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LIST OF ABBREVIATIONS 
ABC Avidin-biotinylated peroxidase complex 
AC Adenylate cyclase 
ACE Angiotensin converting enzyme 
ACh Acetylcholine 
ACTH Adrenocorticotropic hormone 
Ang I Angiotensin I 
Ang II Angiotensin H 
Ang ni Angiotensin EI 
APUD Amine precursor uptake and decarboxylation 
ATP Adenosine 5'-triphosphate 
ATi Angiotensin receptor, type 1 
AT2 Angiotensin receptor, type 2 
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BSA-ATi BSA-ATi peptide conjugate, glutaraldehyde cross-linked 
BSA-AT2 BSA-AT2 peptide conjugate, glutaraldehyde cross-linked 
BSA-BSA BSA-BSA conjugate, glutaraldehyde cross-linked 
cAMP Cyclic adenosine 3,5, -monophosphate 
cGMP Cyclic guanosine 3,5'-monophosphate 
CCK Cholecystokinin 
CVO Circumventricular organ 
DAB 3,3, -Diaminobenzidine tetrahydrochloride 
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ELISA Enzyme-linked immunosorbent assay 
GC Guanylate cyclase 
IP3 Liositol 1,4,5-trisphosphate 
HEPES N-2-Hydroxyethylpiperazine-N-2-ethanesulphonic Acid 
H2O2 Hydrogen peroxide 
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NA Noradrenaline 
NRAS Nonrenin-angiotensin system 
NTS Solitary tract of nucleus 
PAGE Polyacrylamide gel electrophoresis ‘ 
PNMT Phenylethanolamine-7V-methyltransferase 
PBS Phosphate-buffered saline 
PVN Paraventricular nucleus 
RAS Renin-angiotensin system 
SDS Sodium dodecyl sulphate 
SFO Subfornical organ 
TCA Trichloroacetic acid 
TEMED NNN'N'-Tetramethylethylene diamine 
Thy Thyroglobulin 
Thy-ATi Thyroglobulin-ATi peptide conjugate, glutaraldehyde cross-linked 
Thy-AT2 Thyr0gl0bulin-AT2 peptide conjugate, glutaraldehyde cross-linked 
Thy-Thy Thyroglobulin-Thyroglobulin conjugate, glutaraldehyde cross-linked 
TPBS Phosphate-buffered saline containing 0.1 % Triton X-100 
VSMC Vascular smooth muscle cell 
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ABSTRACT 
Polyclonal antibodies against thyroglobulin-conjugates of peptides derived 
from ATi and AT2 angiotensin receptors were obtained from two rabbits. Both 
antisera (Thy-ATi and Thy-AT2) showed strong immunoreactivity to BSA-
conjugates of ATi or AT2 peptide with high titers. The changes in titers with booster 
doses were typical of antibody production, reaching a maximum at the fifth bleeding. 
The antisera also showed weak immunoreactivity towards BSA-BSA conjugate, 
suggesting the presence of antibodies that can recognize the glutaraldehyde linkage 
between the BSAs. AT1/AT2 peptide, but not cholecystokinin or thyroglobulin, 
inhibited the immunoreactivity of affinity-purified Thy-AT1/Thy-AT2 antibodies in a 
concentration-dependent manner. The concentration of free ATi peptide that 
inhibited 50% of the immunoreaction for purified Thy-ATi antibodies was 78.6土 
2.0|4M (n=9). The concentration of free AT2 peptide that inhibited 50% of the 
immunoreaction for the purified Thy-AT2 antibodies was 84.4士 1.8 juM (n=9). 
Application of Thy-ATi antiserum in westem blot analysis revealed three 
immunoreactive proteins with molecular weights of 40，70 and 124 kDa 
respectively. The intensity of these bands was significantly reduced when the 
antibodies had been preabsorbed with immobilized ATi peptides. No 
immunoreactive band was visible when the membrane was incubated with normal 
rabbit serum. Proteins of similar molecular weights have previously been reported to 
bind angiotensin H in various studies. The 70- and 124-kDa bands were present in all 
the tissues tested. Physiological relevance of the 70- and 124-kDa proteins is 
unknown. The 40-kDa band was particularly of interest because its molecular weight 
value was close to that of cloned ATi receptors (Murphy et al., 1991). The 
distribution pattem of the 40-kDa band also suggested its identity as an ATi receptor 
because it was selectively distributed in tissues that were well known to be target 
tissues of angiotensin, namely brain (Phillips, 1987), heart (Whitebread, 1989)， 
kidney (Clark et al., 1991) and adrenal (Whitebread et al., 1989). Since the 40-kDa 
band was absent from pancreas, the responsiveness of rat pancreas to Ang E was 
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evaluated by an assay of a-amylase activity. Li contrast to cholecystokinin (lnM), 
acetylcholine (lOpiM) and carbachol (lO^iM), the presence of angiotensin E (10|uM) 
did not enhance the secretion of a-amylase from isolated pancreas. With the fact that 
no physiological effect of Ang E had been reported in rat pancreas, this lack of 
angiotensin response in the present study lent considerable support to the identity of 
the 40-kDa protein band as a functional ATi receptor. 
The applicability of purified AT2 antibodies in immunohistochemical studies 
was demonstrated by staining the rat adrenal gland with the antibodies. Only the 
chromaffin cells in the adrenal medulla but not the cortical cells were consistently 
stained. Testing of false positive reactions by incubation with normal rabbit serum 
showed no specific staining in the whole gland. The pattern of AT2-immun0reactive 
cells in rat adrenal gland agreed generally with earlier descriptions by 
autoradiographic localization of AT2 receptors. Cords or clusters of stained cortical 
cells were occasionally observed, which might represent migrating differentiating 
cortical cells that expressed AT2 receptors transiently. 
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CHAPTER 1 
1.1 THE RENEV-ANGIOTENSm SYSTEM (RAS) 
The renin-angiotensin system is of principal importance in the regulation of 
cardiovascular function and body fluid composition. The system is activated by an 
enzyme cascade which starts from the cleavage of angiotensinogen CV'allotton, 
1987). 
Angiotensinogen is hydrolyzed by renin to yield the N-terminal decapeptide, 
angiotensin I (Ang I) (Fig. 1.1). Angiotensin I is converted to a vasoactive 
octapeptide, angiotensin H (Ang E), primarily in vascular endothelium ofthe lung 
by angiotensin-converting enzyme which cleaves a dipeptide from the carboxyl-
terminal of Ang I. Ang H is further degraded by angiotensinases into Ang EL 
Angiotensin m (Ang JB), a heptapeptide, lacks only the amino-terminal amino acid 
(aspartic acid) in being identical to angiotensin E (Robertson, 1993). 
The activity of the RAS is primarily determined by the rate ofrenin secretion 
from the kidneys where renin is synthesized, stored and secreted by the 
juxtaglomerular epithelial cells (Hunt et al., 1992). A variety of physiologically 
relevant factors control concordantly renin secretion and renin gene expression in 
these cells. These factors comprise the intrarenal perfusion pressure, a signal 
generated by the adjacent tubular macula densa cells, the activity of renal nerves, 
circulating catecholamines and angiotensin H (Yamaguchi et al., 1992) as well as 
salt intake OOzau et al., 1986a; Dzau et al., 1988). 
Angiotensin E is the primary biologically active hormone of the renin-
angiotensin system. Angiotensin I, once considered inactive biologically, does in fact 
display the activities of angiotensin E, although usually at a higher concentration 
(Robertson, 1993). Angiotensin HI circulates at a lower plasma concentration than 
1 
I 
1 2 3 4 5 6 7 8 9 10 
Angiotensinogen 
H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-
1 _ _ 1 
}f renin 
1 2 3 4 5 6 7 8 9 10 
Ang I H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH 
angiotensin converting 
• enzyme 
1 2 3 4 5 6 7 8 
Ang II 
H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH 
� r angiotensinase 
2 3 4 5 6 7 8 
Ang III 
H-Arg-Val-Tyr-Ile-His-Pro-PheOH 
� ^ angiotensinase 
Inactive peptide fragments 
Fig. 1.1 Outline of the biochemistry of the renin-angiotensin system. Renin 
cleaves angiotensinogen between leucine and valine in positions 10 and 11 to form 
Ang I. The histidine and leucine residues from Ang I are tiien removed by 
angiotensin converting enzyme. Ang III is formed by removal of the aspartic acid 
residue from position 1 by angiotensinase. (Adapted from Robertson, 1993) 
Ang n does, although less is known of its physiological significance. While Ang ni 
is a weaker pressor agent than is AngE, it has equal or greater potency in stimulating 
steroid synthesis in the adrenal (Sarstedt et al., 1975). 
1.2 PHYSIOLOGY AND PATHOPHYSIOLOGY OF 
ANGIOTENSm 
Ang n mediates the physiological effects of the RAS in the cardiovascular, 
endocrine and nervous systems through the stimulation of specific receptors in many 
tissues. Angiotensin E elicits a variety of physiological effects, including intense 
arteriolar vasoconstriction (Hughes & Roth�1971a)�aldosterone biosynthesis and 
secretion (Hughes & Roth�1971a; Aguilera et al., 1980; Whitaker, 1994)， 
catecholamine release (Powis & 0，Brien�1991; Vatta et al., 1991)，stimulation of 
drinking behavior (Simpson & Rottenberg�1973; Mangiapane & Simpson, 1980)， 
glycogenolysis (Breant et al., 1981; Campanile et al., 1982; Gunther, 1984)， 
peripheral modulation of autonomic activity (Hughes & Roth�1971a; Tofovic et al., 
1989; Dceoka & Faber�1993) and alteration of renal function (Clark, 1991). In 
addition, it have been implicated in the regulation of cellular growth (Schelling et 
al., 1991). Ang E increases the expression of platelet-derived growth factor 
(Geisterfer et al., 1988; Naftilan et al., 1989)，Q-fos (Kawahara et al, 1988; Taubman 
et al., 1989) and c-myc (Kawahara, 1988; Naftilan et al., 1989; Gonzalez-Espinosa & 
Garcia-Sainz, 1992), and so appears to play a role in growth and development. 
It has been shown that AngH exerts positive inotropic and chronotropic 
effects in the heart (Saito et al., 1987) of several species. The mechanisms involved 
in the cardiac actions of AngH are its direct effect on myocardial cells, mediated by 
the inhibition of adenylate cyclase (Brock et al., 1985) or by the stimulation of 
phosphoinositol turnover (Alexander et al., 1985), and an indirect effect mediated by 
the release of catecholamines from sympathetic nerves O r^ata et al., 1989). Jn 
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addition to its acute cardiac effect, Ang E has chronic actions in the heart. Ang E 
stimulates protein synthesis and cell growth, which contribute to cardiac hypertrophy 
(Geisterfer, 1988; Fluharty&Reagan�1989; Sadoshima et al., 1993). 
Li addition to its direct effect on the vessel wall, local angiotensin interacts 
with the sympathetic nervous system in a number of ways. Ang E facilitates the 
release of norepinephrine (Ellis & Bumstock�1989) and blocks the reuptake ofthis 
neurotransmitter in the peripheral nerve endings (Casto & Phillips�1986; Vatta et 
al., 1991). 
Although AngE is known predominantly as a cardiovascular regulatory 
peptide, it also has important actions in the central nervous system. All components 
ofthe renin-angiotensin system, including renin, angiotensin-converting enzyme, the 
polypeptide precursor angiotensinogen (Dzau et al., 1986b) and angiotensin receptor 
(Sirett et al., 1977) have been identified in the brain (Bennett & Snyder�1976). 
Stimulation of AngE receptors in the brain evokes many coordinated autonomic, 
endocrine and behavioral responses. Ang H regulates body fluid volume in response 
to hypovolemia. AngE induces thirst (Simpson & Rottenberg, 1973)，elevation of 
blood pressure (Casto & Phillips�1984), vasopressin release (Ramsay et al., 1978; 
Kilcoyne et al., 1980), stimulation of natriuresis and sodium appetite (Clark et al., 
1991)，and the release of adrenocorticotropic hormone (ACTH) (Ramsay et al.� 
1978; Castren & Saavedra，1989) and aldosterone (Livett & Marley，1993). Ang H 
also augments the sensitivity of the baroreceptor reflex (Reid, 1992; Dzau, 1993). 
This function alone has important implications for the control of blood pressure and 
the disease ofhypertension (Phillips et al., 1987). 
Moreover, angiotensin also regulates the release of gonadotropic hormone 
releasing hormones and pituitary hormones such as vasopressin (Gagnon & Hdslcr, 
1974; Kilcoyne et al., 1980), prolactin (Robberecht et al., 1992) and corticotropin 
releasing hormone (Castren & Saavedra, 1989). 
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It was well documented that angiotensin interacts synaptically with 
catecholamines C^atta et al., 1991), prostaglandins (Benabe et al., 1982), and other 
peptides (Phillips, 1987). Several of the structures that contain Ang E receptors, 
including the nucleus of the tractus solitarius, locus coemleus�and peri- and para-
ventricular hypothalamic nuclei, are associated with the central adrenergic system 
(Mendelsohn et al., 1984). Ang E is known to act on peripheral noradrenergic 
neurons to stimulate norepinephrine release (Hughes & Roth�1971a)�and it may 
also be involved in the central regulation of norepinephrine and dopamine release in 
brain regions including the preoptic area (Mendelsohn et al., 1984; Dzau, 1993). 
This interaction is significant for all functions mentioned and leads to alterations in 
motivation (Costall et al., 1990) as well as memory (and possibly learning) (Denny 
et al., 1991). 
Vascular angiotensin is a major pathophysiologic factor involved in various 
vascular diseases. Vascular RAS activity is increased (Fluharty & R^agan, 1989; 
Kimura et al, 1992) in certain forms ofhypertension (Hoffinan et al., 1977; Miyazaki 
et al, 1986; Mullin et al, 1990; Shiota et al, 1992; Taddei et al, 1994)，congestive 
heart failure (Wong et al, 1988; Urata et al., 1989; Qing & Garcia, 1992)，myocardial 
infarction (Cambien, 1992; Richer et al., 1992; Yamagishi et al., 1993)，renal 
vascular dysfunction's (Beaufils, 1992; Jin et al., 1992; Parving, 1992) and 
atherosclerosis (0'Dowd et al., 1993). Ang E may also be responsible for the 
abnormal vascular smooth muscle cell (VSMC) growth (Geisterfer et al., 1988; 
Schelling et al., 1991) seen in hypertension, either indirectly as a consequence of 
elevating blood pressure or directly as a result of receptor-mediated effects on 
VSMC growth (Taubman et al., 1989; Aceto & Baker, 1990; Sadoshima et al., 
1993). 
Studies using Ang E receptor antagonists or inhibitors of ACE or renin have 
demonstrated the importance of the renin-angiotensin system in controlling blood 
pressure and fluid balance under physiologic and pathophysiologic conditions. The 
introduction of orally active angiotensin-converting enzyme inhibitors has 
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demonstrated clearly that pharmacological inhibition ofthe RAS is beneficial for the 
therapeutic treatment of various diseases such as essential hypertension (Ondetti et 
al., 1977) and congestive heart failure CNishimura et al., 1994). Angiotensin has been 
found to play a critical role in many forms ofhypertension as evidenced by the blood 
pressure lowering effect of agents that reduce renin release (e.g. P-adrenoceptor 
antagonists) (Weber, 1992), or more specific agents which antagonize Ang H on 
target cells (e.g. saralasin) (Phillips et al., 1977)，or block its formation (e.g. ACE 
inhibitors) (Ondetti et al., 1977). 
Merruption ofthe RAS as a means of controlling the development ofvarious 
vascular diseases has received a great deal of attention in the recent years. Currently, 
many ongoing clinical trials are examining the role of pharmacological blockade of 
the vascular RAS in human vascular protection (Dzau, 1993). Several ACE 
inhibitors have proven to be clinically effective antihypertensive agents with good 
oral activity and long duration of action. Captopril and enalapril have been shown to 
be effective in managing severe or renin-dependent hypertension and milder forms 
of essential hypertension in which there is no clear activation of the RAS (Qing & 
Garcia, 1992). ACE inhibitors are also used to treat patients with various renal 
diseases (Brunner et al., 1993; Hsueh & Anderson�1993). 
While ACE inhibition is effective in controlling blood pressure, this does not 
occur without some side effects such as cough and angiodema. These side effects are 
believed to be related to the fact that ACE, which is a relatively nonspecific peptidyl 
dipeptidase, is involved in the inactivation of other biologically active peptide 
substrates such as bradykinin fVanhoutte et al., 1993; Young et al., 1993) and 
enkephalins (Ondetti et al., 1977; Stine et al., 1980). Miibition ofACE thus leads to 
potentiation ofbradykinin actions (Yang et al., 1993)，which may be responsible for 
the side effects. Furthermore, angiotensinogen and Ang I may be cleaved to Ang H 
by enzymes other than ACE, so inhibition of ACE alone may not completely prevent 
formation of Ang H. 
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The therapeutic and commercial successes of the ACE inhibitors and their 
lack of specificity stimulated considerable interest in the development of new 
pharmacological inhibitors of the RAS. Renin inhibitors have been designed as 
potential therapeutic agents for treatment of hypertension and congestive heart 
failure (Kleinert et al., 1992); however, although these compounds are effective in 
decreasing blood pressure, they lack adequate oral bioavailability. 
Li contrast, Ang H receptor antagonists represent the most specific means of 
preventing the action of AngH. Saralasin (Sarcosyl^ -alanyl^-Ang H), a specific 
peptide antagonist of AngE, reduces arterial pressure in hypertensive patients with 
high renin levels (Phillips et al., 1977; Brunner et al., 1993). Although peptide 
analogs of Ang H were shown to be potent and specific antagonists of Ang E at its 
receptor, their short half-life, lack of oral bioavailability and partial agonist 
properties (Wong et al., 1990) limited their application as research tools and as 
therapeutic agents. 
The breakthrough came with the discovery of nonpeptide compounds which 
were Ang E receptor antagonists without partial agonist properties. Losartan was the 
first of these agents to enter clinical trials. Losartan (DuP 753) (Fig. 1.2) is the 
potassium salt of 2-n-butyl-4-chloro-5-hydroxymethyl-l-[(2^-(lH-tetrazol-5-
yl)biphenyl-4-yl)methyl]imidazole (Wong et al., 1991). It can effectively reduce 
blood pressure (Christen et al., 1991) and left ventricular hypertrophy (Mizuno et al., 
1992). DuP 753 is orally bioavailable (Christen et al., 1991) and therefore has 
potential for chronic treatment to assess the role of AngE in the manifestation of 
chronic diseases, such as hypertension and congestive heart failure (Qing & Garcia� 
1992; Brunner et al., 1993). Losartan is devoid of agonist activity in hepatocytes 
(Bauer et al., 1991), in isolated vascular (Rhaleb et al., 1991) or non-vascular 
smooth muscle preparations (Rhaleb et al., 1991; Trachte et al., 1990), in 
normotensive rats (Wong et al., 1990) and in humans (Christen et al., 1991). One 
advantage of inhibiting AngH from binding to its receptor is that the system can be 


















































































































































































































































































not affected, there is no potentiation of bradykinin and, therefore, no cough or 
angiodema would be expected during therapy with losartan (Wong et al., 1988; 
Weber, 1992). 
The basic properties of losartan have provided the bench mark against which 
new compounds are compared. Furthermore, these non-peptide AngE receptor 
antagonists have led to the confirmation of the existence of multiple AngH receptor 
binding sites with differential tissue distribution. 
The RAS has long been regarded as an endocrine system with Ang E as a 
circulating hormone. However, the widespread presence (Stometta et al., 1988) and 
expression (Dzau et al., 1986b; Campbell & Habener, 1987; Cassis et al., 1988) of 
components of the RAS as well as the local formation of Ang E (Bakhle, 1968; 
Kifor & Dzau�1987) in various organs led to the hypothesis of a paracrine or 
autocrine function for tissue RAS. Although the evidence for a paracrine function for 
RAS is less than satisfactory, the hypothesis is currently under enthusiastic 
investigation because of its possible significant implications in the therapeutic 
intervention of the RAS as a means of controlling various vascular diseases (Powell 
et al., 1989; Sadoshima et al., 1993). 
9 
1.3 ANGIOTENSm RECEPTORS 
1.3.1 Heterogeneity among Angiotensin Receptors 
As a circulating hormone, AngE exerts its effects through the activation of 
specific angiotensin receptors located predominantly on the cell surface of target 
organs. However, heterogeneity exists among angiotensin receptors. 
The heterogeneity of the Ang H receptor population was foreseen in early 
pharmacological studies showing that effector organs responded to angiotensin 
analogues with up to 2-3 orders of magnitude difference in potency (Chiu & Peach� 
1974; Sarstedt et al., 1975). Other findings in 1980s also suggest that Ang E 
receptors are heterogeneous. For example, there are differential effects of the 
sulfhydryl reducing agent dithiothreitol (Gunther, 1984) on AngE receptor binding in 
various tissues as well as moderate differences in ligand binding affinity in different 
structures within tissues (Chiu & Peach�1974; Devynck et al., 1977; Speth & Kim� 
1990). Multiple mechanisms of signal transduction have also been noted for Ang E. 
Hepatocytes (Campanile et al., 1982; Crane et al., 1982) , vascular smooth muscle 
cells (Alexander et al., 1985; Brock et al., 1985), adrenal cortical cells (Balla et al., 
1989a) and adrenal medullary cells (Capponi et al., 1984) contain AngE receptors 
that activate phospholipase C, catalyzing the hydrolysis of phosphatidylinositol 4,5-
bisphosphate. This action results in the production of inositol 1,4,5-trisphosphate 
(DP3) which mobilizes intracellular Ca�+ (Balla et al., 1989b), and diacylglycerol 
which activates protein kinase C (Kawahara et al.�1988). Cells in the aorta and heart 
are also coupled to guanylate cyclase (GC) (Vesley, 1981). In contrast, neurons 
(Gagnon & Heisler, 1974) and hepatocytes (Breant et al., 1981; Bauer et al., 1991) 
contain Ang E receptors that are coupled to inhibition ofadenylate cyclase (AC) via 
a pertussis toxin-sensitive G-protein, thus preventing an increase in the cellular level 
of cyclic adenosine 3',5'-monophosphate (cAMP). In addition, kidney epithelial 
cells (Benabe et al., 1982) and cells in the rabbit vas deferens (Trachte et al., 1987; 
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Trachte, 1988) respond to Ang E by stimulating production of prostaglandins. 
However, the most compelling indication for AngE receptor subtypes derives from 
the discoveries of nonpeptide Ang H receptor antagonists that are capable of 
distinguishing between AngH receptor subtypes. 
With the development of selective nonpeptide ligands that compete for 
binding with radiolabeled Ang H, it has become apparent that at least two major 
pharmacologically distinct classes of receptors exist for AngE. These AngH receptor 
subtypes have been defined based on affmity for synthetic ligands and sensitivity of 
ligand binding to sulfhydryl reducing agents (Whitebread et al., 1989). For example, 
it has been shown that DuP 753 inhibits ^^ -^Ang E binding in the adult adrenal 
cortex and in vascular smooth muscle, but does not affect binding in the adrenal 
medulla, uterine muscle and some brain areas. Li contrast, PD 123177 (Fig. 1.2), 
which lacks antihypertensive action in vivo, inhibits adrenal medullary and uterine 
binding, but not that in the adrenal cortex and vascular smooth muscle (Chiu et al., 
1989a). 
Now that the Ang E receptors are classified into type I and type H receptors, 
the prototypical antagonists of the two AngE receptor subtypes are the 
biphenylimidazoles typified by DuP 753, and the tetrahydroimidazopyridines 
typified by PD 123177 or structural analogues (Table 1.1) (Bumpus et al., 1991; 
Timmermans et al, 1991). Type I (ATi) and Type E (AT2) receptors bind Ang H with 
high affmity but differentially bind the nonpeptide antagonists DuP 753 and PD 
123177 with a difference in affmity of 1000 fold and more. ATi receptors bind DuP 
753 with high affmity and PD 123177 with low affmity, while AT2 receptors bind 
DuP 753 with low affinity and PD 123177 with high affmity (Feuillan et al., 1993). 
The AT2 subtype also selectively binds CGP42112A (nicotinic acid-Tyr-fNa-
benzyloxycarbonyl-Arg)Lys-His-Pro-Ile-OH, Fig. 1.2) (Whitebread et al., 1991; 
Speth, 1993). 
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A T i A T 2 
Specific antagonist DuP 753 PD 123177 / 
CGP42112A 
I Sulfhydryl reducing DTT diminishes binding DTT enhances binding 
agent sensitivity 
Angiotensin specificity Ang n > Ang m Ang m > Ang n 
Signalling mechanism PhosphoHpase C ？ Guanylate cyclase 
Ca2+ mobilization ？ Tyrosine protein 
Adenylate cyclase phosphatase 
Prostaglandins ？ Prostaglandins 
production production 
Table 1.1 Comparison of ATj and AT�receptors. (Modified from 
Bumpus et al., 1991) 
ATi and AT2 receptors also exhibit different sensitivity to thiol reducing 
agents. The AT2 binding sites are resistant to reduction by dithiothreitol (DTT), 
while binding to ATi receptors declines in the presence ofDTT (Chiu et al., 1989b; 
Whitebread et al., 1989). Distributions ofthe ATj and AT^ receptor subtypes are 
widespread. The presence and proportion of these receptors vary significantly among 
different tissues ofthe same species and within the same tissue of different species. 
The affinity constants of the ligands vary little between tissues or species, which is 
one ofthe main criteria used for receptor classification (Sirett et al., 1977; Raizada et 
al., 1981; Campanile et al., 1982; Wright et al., 1983). 
1.3.2 Differential Distribution of Subtypes 
The ATi receptor is the predominant subtype in the adrenal cortex 
(Whitebread et al., 1989; Chang & Lotti�1990)，vasculature (Whitebread et al., 
1989; Nozawa et al., 1994)，kidney (Zhuo et al, 1994) and liver (Dudley et al, 1990; 
Bauer et al., 1991)，whereas the AT2 receptor predominates in the adrenal medulla 
(Whitebread et al, 1989; Chang & Lotti, 1990) and ovary of rats (Pucell et al., 
1991)，in the developing rat fetus (Feuillan et al., 1993; Grady & Kalinyak�1993), in 
PC12 rat pheochromocytoma cells (Webb et al., 1992) and in the human uterus 
(Whitebread, 1989; Rowe et al., 1991; Summers et al., 1991). 
Using in vitro autoradiography, many sites in the rat brain believed to be 
related to the central actions of Ang H were shown to contain predominantly ATi 
receptors; these include the sites involved in the dipsogenic actions ofAng U (Hartle 
& Brody, 1984)，such as the forebrain circumventricular organs consisting of 
organum vasculosum of the lamina terminalis (OVLT), subfornical organ (SFO), and 
median preoptic nucleus (MnPO) (Fig. 1.3). Areas involved in the neurogenic 
control of blood pressure, such as the lateral parabrachial nucleus (LPB), dorsal 
motor nucleus of vagus (DMNV), area postrema (AP) and nucleus of the solitary 







































































































































































































































































































































































































































1991; Song et al, 1992; Steckelings et al, 1992; Aldred et al., 1993). High levels of 
predominantly AT! receptors were also found in the anterior pituitary, the 
periventricular & paraventricular nuclei of the hypothalamus, supraoptic nucleus, the 
ventral hippocampus, substantia gelatinosa of the trigeminal nucleus, nucleus ofthe 
lateral olfactory tract, the rostral and caudal ventrolateral medulla (Gehlert et al., 
1990; Rowe et al, 1990; Gehlert et al, 1991; Rowe et al., 1991). 
The locus coeruleus (LC) which is the major source of noradrenergic fibre 
projection throughout the CNS contains predominantly AT2 receptors (Fig. 1.3). 
Other sites which contain predominantly AT2 receptors are in the lateral septum, the 
thalamus, ventral posteromedial thalamic nucleus fVPM), mediodorsal thalamic 
nucleus (MD), subthalamic nucleus (STh), superior colliculus (SC), inferior olive 
(10)，medial geniculate nucleus (MG), bed nucleus of the accessory olfactory 
nucleus (BAOT) and medial amygdala (Gehlert et al., 1991; Song et al., 1991； 
Ambuhl et al., 1992; Steckelings et al, 1992). Several areas ofthe brain appeared to 
contain both receptor subtypes, including the superior and inferior colliculi, and the 
olfactory bulb (Gehlert, 1991). 
1.3.3 Molecular Structure of Subtypes 
The structure ofATi receptor has recently been elucidated from the cloning 
ofthe cDNA or genes from a number of species (Iwai et al., 1991; Murphy et al., 
1991; Sasski et al., 1991). These AT! receptors are highly homologous and display 
similar features: the ATi receptor consists of 359 amino acids with a molecular 
weight of approximately 41,000 before post-translational processing. Hydropathy 
plots ofthe ATi receptor indicated that they contain seven putative transmembrane 
domains, belonging to the G protein-coupled receptor family (Fig. 1.4). 
There are four cysteine residues, one in each ofthe extracellular loops ofthe 




























































































































































































































bridges and probably account for the sensitivity of the ATi receptor to dithiothreitol. 
There are three potential extracellular N-linked glycosylation sites in the third 
intracellular loop and the cytoplasmic tail (Sasski et al., 1991). Several serine and 
threonine residues are in the second and C-terminal cytoplasmic domains for 
possible regulatory phosphorylation. Other notable features include the hydrophilic 
N-terminal sequence, the short third cytoplasmic loop, and a cysteine residue in the 
C-terminal region as a possible palmitoylation site (Ovchinnikov et al., 1988; 
0'Dowd et al., 1989). 
Subsequent genomic analyses and homology cloning studies demonstrated 
that the ATi receptor comprises two isoforms, named ATiA and AT^ with a striking 
similarity to each other in amino acid structure, pharmacological specificity, and 
signal transduction mechanism (Fig. 1.4) (Iwai & hagami�1992a; Sasamura et al., 
1992; Chiu et al., 1993). They have different patterns of expression (Kakar et al., 
1992b), in terms of tissue specificity (Iwai et al., 1992b; Kakar et al., 1992a; Kitami 
et al., 1992; Mukoyama et al., 1993; Burson et al., 1994; Conchon et al., 1994) and 
expression during development (Shanmugam et al., 1994b). 
ATi receptor cDNA was also cloned from a rat fetus expression library 
(Mukoyama et al., 1993). The cDNA encoded a unique 363-amine acid protein with 
pharmacological specificity, tissue distribution, and developmental pattem of the 
AT2 receptor. It is 34% identical in amino acid sequence to the ATi receptor (Fig. 
1.5), sharing a seven-transmembrane domain topology (Fig. 1.6). A review ofprior 
data on other receptors suggests that this receptor may belong to a unique class of 
seven-transmembrane receptors (including dopamine D3) for which G protein 
coupling has not been demonstrated (Grady and Civelli, 1992). All members ofthis 
class exhibit fetal and developmental and/or neuronal-speciflc expression 


































































































































































































































































































































































































































































































































































































































































































































































1.3.4 Signal Transduction Mechanism 
The intracellular signal transduction mechanism of AT2 have not been well 
defined. Stimulation of the cloned AT2 receptor failed to increase JP3 or intracellular 
calcium or to inhibit adenylate cyclase (Webb et al., 1992; Mukoyama et al., 1993). 
Tsutsumi and Saavedra (1992) have reported the existence of two AT2 receptor 
subtypes. The AT2a subtype is sensitive to guanine nucleotides and pertussis toxin 
in a manner similar to several G-protein linked receptors (Bottari et al., 1991). The 
AT2b subtype is insensitive to guanine nucleotides and pertussis toxin and conforms 
more to the criteria for the AT2 receptor (Speth, 1993). Recent data also report 
coupling of a subgroup of central AT2 receptors to G proteins (Steckelings et al., 
1992). These receptors were localized in the ventral thalamic and medial geniculate 
nuclei and in the locus coeruleus, while AT2 receptors in the inferior olive were not 
coupled to G proteins. 
In fact, it was recently showed that stimulation of the AT2 receptor led to a 
decrease of cGMP levels (Summers et al., 1991; Bottari et al., 1992). This decrease 
may be caused by an inhibition of particulate guanylyl cyclase following the 
stimulation ofaphosphotyrosine phosphatase (Bottari et al” 1992; Steckelings et al., 
1992). Stimulation 0fAT2 was also reported to lead to an increase in release of 
prostaglandins in human astrocytes (Jaiswal et al., 1991). 
Multiple mechanisms of signal transduction have been noted for ATi 
receptors. In peripheral tissues, ATi receptors interact with G proteins, inhibiting 
adenylyl cyclase activity (Bauer et al., 1991) and stimulating phospholipase C, 
phospholipase A2 and phospholipase D (Ohnishi et al., 1992). These, in tum, cause a 
decrease in cellular cAMP (Ohnishi et al” 1992), and a stimulation ofboth JP3 and 
diacylglycerol generation (Webb et al., 1993) as well as prostaglandin synthesis 
(Trachte et al” 1990). The generation of the second messengers inositol 
trisphosphate and diacylglycerol are involved in intracellular Ca�+ mobilization and 
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protein kinase C activation (Kawahara et al., 1988)，respectively. It should be noted 
that the activation ofthese pathways has been associated with increased cell growth 
(Kaibuchi et al., 1986). 
1.3.5 Physiological Functional Correlates 
Since the receptor subtypes are coupled to different second messenger 
systems, they are likely to subserve different functions. In fact, the existence ofAng 
n receptor subtypes might be able to account for the diverse actions ofAng H. 
Hi the adult rat, the ATi receptor predominates in abundance and accounts for 
the majority of the physiological actions mediated by angiotensin H (Wong et al., 
1990; Steckelings et al., 1992). These actions include the maintenance of circulatory 
homeostasis through its effects on vascular resistance and electrolyte balance (Clark 
et al., 1991). DuP 753, a specific antagonist for ATi receptors, antagonizes all ofthe 
known physiological actions of Ang E, including aldosterone release by adrenal 
glomerulosa cells (Wong et al., 1990; Balla et al, 1991; Hajnoczky et al, 1992) and 
contractile responses of isolated vascular (Wong et al., 1990; Rhaleb et al., 1991； 
Liu, 1993) and non-vascular smooth muscle (Trachte et al., 1990; Wong et al., 1990; 
Rhaleb et al., 1991) as well as cardiac muscle (Dudley et al., 1990). DuP 753 also 
blocks, in a dose-related fashion, the blood pressure response to Ang H (Mizuno et 
al., 1992). 
The presence ofATj subtypes with little or no AT� subtypes in brain nuclei 
at which AngE mediates its pressor and dipsogenic actions ( the subfornical organ, 
organum vasculosum of the lamina terminalis, paraventricular nucleus of the 
hypothalamus and solitary tract nucleus ), suggests that the ATj subtype mediates 
these actions of Ang H in the brain (Gehlert et al., 1991). 
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Whereas the ATi receptor mediates the AngH-induced alterations in pressor 
responses, catecholamine and aldosterone secretion, and drinking behaviour, the 
exact physiological function of the AT2 binding sites as yet remains unknown. This 
receptor was once considered by many as being a non-functional binding site. The 
high density of AT2 receptors present in a wide variety of tissues, including rat 
adrenal medulla (Chiu et al., 1989a)�rat brain (Steckelings et al., 1992), rat ovarian 
granulosa cells (Pucell et al., 1991), rabbit and human uterus (Whitebread et al., 
1994)，rat fetus (mesenchymal tissues) (Millan et al, 1989; Shanmugam et al, 
1995), and certain types of cell lines (Webb et al., 1992) suggests that it is 
physiologically significant. 
Meed, the high abundance and transient expression of AT2 receptor in the 
developing fetus suggest a major role of Ang H in fetal growth and differentiation 
(Millan et al., 1989; Brechler et al, 1993). The high density 0fAT2 in rat ovarian 
granulocytes (Pucell et al., 1991) and human uterus (Whitebread et al., 1994) may 
also indicate an important effect of Ang H on the reproductive system. 
It became clear that the AT2 receptor is also linked to biological responses 
when it was reported that this receptor mediates a decrease of cellular cGMP in 
neuronal cell cultures (Summers et al., 1991). This receptor has also been shown to 
mediate Ang H stimulation of phosphotyrosine phosphatase activity (Bottari et al., 
1992) and inhibition of particulate GC activity in PC12w cells (Brechler et al, 
1993). In human astrocytes, prostaglandin synthesis appears to be related to the 
activation 0fAT2 receptors (Jaiswal et al., 1991). Other reports have also shown that 
there were Ang H responses which were selectively blocked by PD123177 or 
PD123319 but not by losartan. For example, in neuron cultures from neonatal rat 
brain�Ang H-induced increase in K+ current (Kang et al., 1992) was completely 
blocked by PD123177 but not by DuP753. 
Because ofthe location and timing of expression ofthe fetal AT2 sites, it has 
been suggested that they may be involved in fetal growth. Although the ATi receptor 
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predominates in the adult rat, the developing rat fetus has a substantially greater 
abundance 0fAT2 receptors (Feuillan et al., 1993). The expression 0fAT2 receptors 
is higher in early development, whereas ATi receptors are similarly expressed in 
young and adult rats. These AT2 receptors are maximal during the last days of 
gestation and decline rapidly after birth. The expression of AT2 receptors are 
enhanced in fetal skeletal muscle, skin, and aorta (Grady & Kalinyak�1993). These 
pattems ofexpression of the AT2 receptor suggest an important role in growth and 
development (Shanmugam et al., 1995), 
The possible role of AT2 in drinking was suggested by studies with AT2 
mutant mice (Hein et al., 1995). The drinking behaviour of knockout mice were 
found to be the same in daily water intake compared with normal mice when water 
was freely available. On the contrary, the drinking response was significantly 
impaired in the AT2 mutant mice compared to normal after water deprivation. The 
study also revealed a significant decrease in the exploratory activity of the AT2 
mutant mice compared with non-mutant mice. Another study also revealed increased 
blood pressure, increased pressor sensitivity to Ang H, attenuated exploratoty 
behaviour and lowered body temperature in mice with disruption ofthe AT2 gene 
(Ichiki et al., 1995). However, the mutant did not show any impairment in 
development despite the implication 0fAT2 receptor in fetus development (Grady & 
Kalinyak�1993; Shanmugam et al., 1995). The physiological significance of these 
AT2-recept0r-mediated functions clearly awaits clarification. 
1.4 A m OF STUDY 
The investigation of angiotensin receptor biology was complicated by the 
heterogeneity existed within receptor subtypes (ATu and ATig) and the diversity in 
the signal transduction pathways. The existence of multiple subtypes of the ATi 
receptor leaves the possibility open that activation ofmultiple transduction systems 
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occurs through distinct subtypes of the ATi receptor. The apparent paradox of 
unknown physiological function associated with AT2 receptor and yet its distinct 
distribution pattern and coupling to various signally mechanism has also received 
considerable interest recently. 
Most of what we know about angiotensin receptors came from 
pharmacological studies using specific receptor antagonists. This approach presents 
certain disadvantages in which the inability to distinguish between isoforms within 
receptor subtypes (e.g. ATiA and ATie) is one ofthose. The present study attempted 
to unravel the unsolved enigma by an immunochemical approach. 
Lmnunohistochemical techniques are advantageous in the sense that they can lead to 
the determination ofthe exact distribution pattern ofantigens in question because of 
the specificity of antibodies towards known genotypes. Antibodies obtained from 
active immunization can also be applied in immunoprecipitation studies to 
determine the signaling mechanisms coupled to angiotensin receptor subtypes 
(especially for AT2), and functional perturbation studies to study the physiological 
fUnctions of receptor subtypes (AT! and AT2) or even ofisoforms (ATiA and ATie). 
Because of the breakthrough in sequencing the Ang E receptors, it is now 
possible to study various aspects of the receptor by immunoreactivity to an antibody 
made to part or all ofthe receptor sequence. Antibodies were raised against peptide 
of part of Ang E receptor proteins as a first step. The presence and yield of the 
desired antibody was tested for by Enzyme-Linked tnmunosorbent Assay (ELISA). 
To further characterize the antisera obtained, the applicability of the antisera in 
Westem blotting was evaluated. The ultimate test was the quality of 




A short sequence of amino acids was chosen from each of the proteins 
translated from reported sequences of cloned cDNA ofATi (Murphy et al, 1991) 
and AT2 (Mukoyama et al., 1991) receptors. These amino acid sequences are each 
specific for their respective receptor protein. The peptide derived from AT, receptor 
contains 12 amino acid residues corresponding to 333rd - 344th amino acids. That of 
AT2 receptor contains 11 amino acid residues corresponding to the 341st - 351st 
amino acids. With reference to the seven-transmembrane a-helices model of 
angiotensin receptors (Murphy et al., 1991)，both peptides are located at the 
intracellular C-terminal tail of the putative protein (Fig. 2.1). 
The commercially synthesized peptides were glutaraldehyde-linked to carrier 
protein and then were used to immunize rabbits. The antisera thus obtained were 
initially characterized by ELISA to determine the titer of crude antisera and the 
specificity of affmity-purified antibodies. 
2.2 METHODS 
2.2.1 Preparation of Antisera 
2.2.1.1 Preparation of Peptide Conjugates 
The C-terminal peptides of ATi and AT2 were synthesized commercially 
(Research Genetics). Solutions of thyroglobulin, ATj, and AT2 peptides (5mg/ml) 
were prepared in a phosphate-buffered saline (PBS) (0.1 M Na2HPO4, 0.9% NaCl, 
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glutaraldehyde in PBS was added to initiate cross-linkage. The mixture was left for 
incubation at room temperature for 1 hour. Cross-linking reaction was terminated 
with ethanolamine at a final concentration of 0.2M in PBS for 1 hour. 
The reaction mixture was dialyzed against PBS overnight with three or four 
changes of PBS. The protein concentration of the peptide-carrier protein conjugates 
was determined by the method ofFolin-Lowry (Lowry et al., 1951). Then, fractions 
of 200^g protein were aliquoted and lyophilized. The lyophilized peptide conjugates 
were stored at -20�C until use. 
2.2.1.2 Protein Determination 
The concentration of protein was determined by the method of Lowry & 
coworkers (1951). Protein samples were solublilized with an equal volume o f 2 N 
NaOH for 30 minutes. Appropriately diluted samples (100^1) were mixed with 1ml 
reagent A (2% Na2CO3, 0.02% CuSO4, 0.04% K-Na Tartrate). After incubation at 
room temperature for 10 minutes, lN Folin reagent (100^1) (Sigma) was added and 
mixed immediately. After 30 minutes of incubation at room temperature, absorbance 
was measured at 750nm. BSA (Liitial fractionation by heat shock; fraction V; purity 
98-99%) (Sigma) was used as the protein standard. 
2.2.1.3 Immunization of Rabbits with Peptide Conjugates 
Lyophilized thyroglobulin-peptide conjugate (200^g) was dissolved in 0.6ml 
Dulbecco's phosphate-buffered saline (DPBS; 1.47mM KH2PO4, 8.03mM 
Na2HPO4, 137mM NaCl, 2.68mM KC1, pH7.4). The conjugate solution was mixed 
with 0.6ml Freund's adjuvant (Sigma Chemicals) until a thick emulsion was 
obtained (Clausen, 1988). The emulsion was immediately used for immunization. 
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Four injections were applied subcutaneously near alternating left and right 
hind legs. A subsequent boosting dose was applied every month. Freund's complete 
adjuvant was used for emulsion in the first immunization, and incomplete adjuvant 
was used for subsequent immunizations. Freund's adjuvant was used to excite the 
antigenic response of reticuloendothelial system of the rabbits (Clausen, 1988). 
2.2.1.4 Collection of Rabbit Sera 
Lmnunized rabbits were bled on the tenth day after the first immunization 
and after each boosting dose. With the rabbit restrained in a rabbit restrainer 
(^algene), blood was collected from the central veins of the rabbit's ears. 
The collected blood was allowed to clot at room temperature. Clotted blood 
was then centrifuged at 1500 xg for 10 minutes and subsequently at 13000 xg for 10 
minutes to remove blood-clot and cell debris. The resulting rabbit serum was 
aliquoted into 1.5ml fractions and stored frozen at -20°C until use. 
2.2.1.5 Affinity Purification ofAntisera 
Antisera from immunized rabbits were purified by affinity chromatography 
to obtain monospecific antibodies that recognize only ATi or AT2 peptides. 
An affinity column was prepared by cross-linking aminoalky agarose gel 
(BIO-RAD) with ATi or AT2 peptides (Research Genetics) by carbodi-imide (O.lM) 
as suggested by the manufacturer. Carbodi-imides ( R.N:C:N.R' ) crosslinks a 
carboxyl group with an amino group with elimination of water to give a peptide and 
the corresponding urea (R.NH.CO.NHR' ) (Clausen, 1988b). 
Antiserum (0.5 - 2ml) was added to the peptide-linked gel matrix. 
Antibodies were then allowed to adsorb onto the immobilized peptides by rotating 
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the column along the longitudal axis gently ovemight. Unbound antibodies were 
washed away with Dulbecco's phosphate-buffered saline (DPBS, pH7.4) until the 
absorbance at 280 nm of the collected lml- fractions reached zero. Adsorbed 
antibodies were eluted with a glycine buffer (O.lM glycine, pH2.5). The eluants 
collected was then dialyzed against DPBS ovemight. BSA (5^g/ml) was added to 
the dialyzed eluant as carrier protein. The purified antibodies were stored at 4°C until 
use. The column was regenerated by washing with 100ml DPBS. 
2.2.2. Enzyme-Linked Immunosorbent Assay (ELISA) 
2.2.2.1 Titer Determination 
Antigens were dissolved in a coating buffer (15mM Na2CO3, 17mM 
NaHCO3, pH9.6) to give a concentration of 25|^ gAnl. 96-well plates (Coming) with 
flat-bottoms were coated with the appropriate antigens by incubating for 2 hours at 
37°C. Unbound antigens were removed from the wells by two washes with a borate 
buffer (15mM Na2B4O2, 140mM H3BO3, 137mM NaCl, 3mM KC1, 5% dry 
skimmed milk powder, 0.05% NP-40, pH8.0). Dry skimmed milk was included in 
the buffer to minimize nonspecific binding. 
Appropriately diluted antisera from rabbits immunized with Thy-ATi or Thy-
AT2 conjugate were incubated in the wells at 37°C ovemight. Unbound antibodies 
were removed by two washes with the borate buffer. Peroxidase-conj ugated goat 
anti-rabbit IgG antibody (2000 folds diluted in borate buffer) (DAKO) was incubated 
in the wells at 37°C for 2 hours. Unbound goat antibodies were removed by two 
washes with borate buffer followed by one wash with phosphate-buffered saline 
OpH7.4). 
o-Phenylenediamine (Sigma) (lmgy'ml) in a citrate-phosphate buffer (24mM 
citric acid, 51mM Na2HPO4, pH5.0) containing 0.024% H2O2 was used as substrate 
for peroxidase. The substrates were allowed to incubate at room temperature for 10 
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minutes in the dark. The reaction was then stopped by adding 40% H2SO4. 
Lmnunoreactivity was taken as the absorbance of the reaction mixture at 490nm by a 
microplate reader (BIO-RAD). 
2.2.2.2 Specificity Determination 
Specificity of antisera was determined as in the standard ELISA protocol 
described above, except that purified antibody was coincubated with various 
concentrations of competing antigens (lnM-lOO^M): ATi peptide, AT2 peptide, 
cholecystokinin (CCK) or thyroglobulin. Purified antibodies were diluted to give an 
absorbance at 490nm of 1.0 approximately which was defined as 100% binding in 
the ELISA assay. 
2.3 RESULTS 
2.3.1 Preparation of Antisera 
Antisera against angiotensin receptors were obtained from two rabbits. One 
of the rabbits was immunized with ATi peptide conjugated to thyroglobulin (Thy-
ATi), and the other with AT2 peptide conjugated to thyroglobulin (Thy-AT2). A total 
of 10 bleedings were collected from the rabbit immunized with Thy-ATi, while only 
9 bleedings were obtained from the rabbit immunized with Thy-AT2 because the 
rabbit had died before the tenth bleedings was collected. 
2.3.2 Affinity Purification ofAntisera 
Affinity purification of the antisera was carried out to obtain monospecific 
antibodies. For both the Thy-ATi and Thy-AT2 antisera, the absorbance at 280 nm of 
the initial fractions was very high, indicating a high protein content of the fractions 
washed off from the matrix (Fig.2.2 and Fig, 2.3). Continuous washing with DPBS 
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(pH 7.4) resulted in a decrease in absorbance. Lmnediately after switching to an 
acidic elution buffer of glycine, there was a second peak indicating elution of 
peptide-specific antibodies. 
2.3.3 ELISA 
2.3.3.1 Titer Determination 
Since the antisera were raised against thyroglobulin conjugates of peptides, 
the antisera would probably cross-react with thyroglobulin. Hence, BSA-conjugates 
of peptides were used as the coating antigen to assay the immunoreactivity of the 
antisera towards the receptor peptides. BSA-BSA conjugate was used as the control 
coating antigen to determine the immunoreactivity of the antisera towards the 
glutaraldehyde linkage. 
2.3.3.1.1 Thy-ATi Antiserum 
Thy-ATi antiserum showed strong immunoreactivity to BSA-ATi conjugate 
but only weak immunoreactivity to BSA-BSA conjugate (Fig. 2.4). Moreover, the 
immunoreactivity of the antiserum to BSA-ATi conjugate decreased with increasing 
dilution of the antiserum. However, dilution of the antiserum had no distinct effect 
on the immunoreactivity to BSA-BSA conjugate. Similar results were obtained with 
all the other bleedings. Avidity of the antiserum rose during the early bleedings and 
reached a maximum at the fifth bleeding, then declined (Fig. 2.5). Note that avidity 
was measured as the dilution fold which gave absorbance at 490nm of 1.0 
approximately. Since the amount of antisera obtained from the first and second 
bleedings was small, their corresponding titers were not determined. 
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2.3.3.1.2 Thy-AT2 Antiserum 
The Thy-AT2 antiserum also showed strong immunoreactivity towards BSA_ 
AT2 conjugate but weak immunoreactivity towards BSA-BSA conjugate (Fig. 2.6). 
While increasing dilution of the Thy-AT2 antiserum led to a decrease in its 
immunoreactivity towards BSA-AT2 conjugate, its immunoreactivity towards BSA-
BSA conjugate was not apparently affected. Similar results were obtained with all 
the other bleedings. The titer of different bleedings varied with a similar pattem to 
that ofThy-ATi antiserum. The titer reached a maximum at the fifth bleeding (Fig. 
2.7). Since the amount of antisera obtained from the first and second bleedings was 
small, their corresponding titers were not determined. 
2.3.3.2 Specificity Determination 
Specificity of the purified antibodies was evaluated by coincubating the 
antibodies with competing antigens. CCK was employed to determine the cross-
reactivity of the purified antibodies towards a polypeptide unrelated to AT1/AT2 
peptide. Cross-reactivity of the purified antibodies towards the carrier-protein was 
evaluated by co-incubating thyroglobulin with the antibodies. 
2.3.3.2.1 Thy-ATi Antibodies 
ltacreasing concentration of ATi peptide inhibited the immunoreactivity of 
purified Thy-ATi antibodies in a concentration-dependent manner (Fig. 2.8). The 
concentration of free ATi peptide that inhibit 50% of the immunoreaction for 
purified Thy-ATi antibodies was 78.6土 2.0|iiM (n=9). On the contrary, neither CCK 
nor thyroglobulin showed inhibition of immunoreaction for all the concentrations 
tested. 
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Figure 2.2 A representative elution profile of affinity purification of Thy-ATi 
antiserum. Antiserum (2ml) from the 5th bleeding was allowed to adsorb onto 
peptide-conjugated gel matrix. Non-specific antibodies were washed away with 
DPBS (pH7.4) ( ‘ �unt i l absorbance at 280nm dropped near to zero. Glycine buffer 
(O.lM, pH2.5) (>lr) was used to elute antibodies adsorbed, lml-fractions were 
































































































Figure 2.3 A representative elution profile of affinity purification of Thy-AT2 
antiserum. Antiserum (2ml) from the 5th bleeding was allowed to adsorb onto 
peptide-conjugated gel matrix. Non-specific antibodies were washed away with 
DPBS (pH7.4) (i) until absorbance at 280nm dropped near to zero. Glycine buffer 
(O.lM, pH2.5) ( i ) was used to elute antibodies adsorbed, lml-fractions were 

















































































Figure 2.4 Immunoreactivity of Thy-ATi antiserum towards BSA-ATi ( • ) and 
BSA-BSA � conjugates. Antiserum from the 5th bleeding was used. Values were 
mean 土 S.E.M. from 3 separate experiments performed in triplicates. Similar results 
have been obtained in 24 separate experiments with the bleedings three to ten. For 
some of the data values, the error bars are not apparent because they are smaller in 



























































































Figure 2.5 Titers of Thy-ATi antisera against different bleedings. BSA-ATi 
conjugate was used as the coating antigen. Antibody titers were defined as the 
dilution of antiserum that gave a value of 1.0 for absorbance at 490nm in the ELISA. 
Titer values were obtained from individual dilution curves. Values were mean 士 


















































































































Figure 2.6 Immunoreactivity of Thy-AT2 antiserum towards BSA-AT2 ( • ) and 
BSA-BSA � conjugates. Antiserum from the 7th bleeding was used. Values were 
mean 土 S.E.M. from 3 separate experiments performed in triplicates. Similar results 
have been obtained in 21 separate experiments with the bleedings three to nine. For 
some of the data values, the error bars are not apparent because they are smaller in 












































































































Figure 2.7 Titers of Thy-AT2 antisera against different bleedings. BSA-AT2 
conjugate was used as the coating antigen. Antibody titers were defined as the 
dilution of antiserum that gave a value of 1.0 for absorbance at 490nm in the ELISA. 
Titer values were obtained from individual dilution curves. Values were mean 土 















































































































Figure 2.8 Inhibition of binding of Thy-ATi antibodies. The microtiter plate was 
coated with BSA-ATi. The antiserum was coincubated with competing antigens: 
Thyroglobulin (•)，CCK (M), and ATi ( • ) . Inunimoreaction in the absence of 
competing antigen was adopted as 100% binding. Antibodies from the 4th，6th, and 
8th bleeding were used in the assay. Three separate experiments were performed for 
each bleeding, and the graph showed the average value from the 3 bleedings. 
Dilution of the antibodies that gave absorbance at 490nm around 1.0 at 100% 
binding were used. Values were mean 土 S.E.M. (n=9) performed in triplicates. For 
some ofthe data values, the error bars are not apparent because they are smaller in 





















































































































































Figure 2.9 Wiibition of binding of Thy-AT2 antibodies. The microtiter plate was 
coated with BSA-AT2. The antiserum was coincubated with competing antigens: 
Thyroglobulin (•)，CCK 脚，and AT2 ( • ) . Immunoreaction in the absence of 
competing antigen was adopted as 100% binding. Antibodies from the 4th，6th，and 
8th bleeding were used in the assay. Three separate experiments were performed for 
each bleeding, and the graph showed the average value from the 3 bleedings. 
Dilution of the antibodies that gave absorbance at 490nm around 1.0 at 100% 
binding were used. Values were mean 土 S.E.M. (n=9) performed in triplicates. For 
some of the data values, the error bars are not apparent because they are smaller in 


























































































































































2.3.3.2.2 Thy-ATi Antiserum 
AT2 peptide inhibited the immunoreactivity ofpurified Thy-AT2 antibodies 
in a concentration-dependent manner (Fig. 2.9). The concentration of free AT2 
peptide that inhibit 50% of the immunoreaction for the purified Thy-AT2 antibodies 
was 84.4士 1.8 ^M (n=9). However, both CCK and thyroglobulin did not affect the 
immunoreaction even at as high a concentration as lOO^M. 
2.4 DlSCUSSIONS 
Specificity ofthe antibodies raised is extremely important for interpretation 
ofresults from downstream experiments where the antibodies are applied. Careful 
selection of peptide sequence is crucial for successful collection of antibodies 
specific for the intended antigen and subsequent application of the antibodies in 
various immunochemical experiments. Ifamino acid residues are shared by both the 
intended antigen and other antigens, antibodies directed at such sequences will bind 
to both the specific and non-specific antigens, resulting in serological cross-
reactivity. The peptide sequences selected in the present study have been compared 
for homology using a Blastp program with the Swiss Prot protein database. The only 
significant match found for AT1/AT2 peptides was with the receptor itself, indicating 
high specificity of the peptide sequences for the AT1/AT2 receptors. 
Since thyroglobulin conjugates ofthe peptides were used to immunized the 
rabbits，the antisera collected should contain antibodies that react with the carrier 
protein. Therefore, BSA conjugates ofATi and AT2 peptides were used as coating 
antigen in ELISA to avoid immunoreaction with the carrier-protein. 
Both antisera recognized conjugated AT! or AT2 peptides (Fig.2.4 and 2.6) 
with high titers (Fig.2.5 and 2.7). The changes in titers with booster doses were also 
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typical of antibody production. The primary immune response resulted in formation 
of a low concentration of IgM antibodies indicated by the low titer obtained from 
titer tests (Clausen, 1988). Further challenge of the immune system resulted in class 
switching to the more useful IgG class of antibodies, which were also produced at 
much greater concentrations and higher affmity (high titer) (Abbas et al., 1991). 
Further booster immunizations were carried out as necessary in an attempt to 
maximize antibody production. A high titer of specific antibody is important for 
immimohistochemistry, since dilution of the preparation may ultimately be necessary 
to reduce or avoid some nonspecific staining. 
It was noted that the titer decreased after eighth injections probably because 
of secondary amyloidosis (Hyde, 1992). Therefore, immunization was stopped after 
the tenth bleeding. 
It should be noted that the definition of antibody titer is at best semi-
quantitative. The term is most often used as a means of indicating the effective 
amount of specific antibody in an antiserum (Liddell & Weeks，1995). However, the 
heterogeneity of polyclonal antibody populations precludes the ability to define 
antibody concentrations in absolute terms, and so the titer is defined as that dilution 
of antiserum which is required to bind a given quantity of antigen under defmed 
conditions. A polyclonal antiserum may well have a mixture ofantibodies in it, such 
as antibodies to the whole antigen and to different parts of it, antibodies to the 
carrier protein, and natural antibodies already present in the blood of the animal. 
Hence, titer does not reflect the actual affmity of the antibodies. 
On the other hand, the antisera did show immunoreactivity towards BSA-
BSA conjugate. This suggested that the antisera contained antibodies that can 
recognize the glutaraldehyde linkage between the BSAs. Since antibodies that 
recognize thyroglobulin and glutaraldehyde existed in the antisera, affmity 
chromatography was used to purify the antisera in order to obtain monospecific 
antibodies that recognize only the AT1/AT2 peptides. 
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Purified antibodies were used for further evaluation ofthe specificity ofthe 
antisera. Since antibodies bound with free antigens are unavailable to coated 
antigens, purified antibodies were allowed to coincubate with varying increasing 
concentrations of free competing antigens to determine specificity ofthe antibodies 
in competitive ELISA. The presence of free ATi or AT2 peptides, but not CCK or 
thyroglobulin, led to a reduction in the immunoreactivity ofthe purified antibodies 
towards the BSA-conjugate of ATi or AT2 coated on the plates. This suggested the 
existence ofantibodies in the purified antibodies that could recognize the native ATi 
or AT2 peptide. 
It was noted that free native ATi and AT2 peptides had been unable to 
abolish completely the immunoreactivity in competitive ELISA. A possible reason is 
that the concentration of free peptides used was not high enough. Another possibility 
that could not be excluded is that the antisera contained antibodies that recognize 
peptide-carrier protein conjugates but not the free peptides. This should, in fact, be 
expected because the antisera did contain antibodies that recognize the 
glutaraldehyde linkage between peptides and carrier proteins in the conjugate, as 
revealed by the immunoreactivity towards BSA-BSA conjugate shown in Fig. 2.4 
and Fig. 2.6. 
As mentioned earlier, antibodies that recognize thyroglobulin should exist in 
the unpurified antisera because thyroglobulin was originally used as the carrier 
protein in immunization of the rabbits. However, co-incubating thyroglobulin failed 
to inhibit the immunoreaction of the purified antibodies from both Thy-ATi and 
Thy-AT2 antisera towards the receptor peptides as shown by Fig. 2.8 and Fig. 2.9. 
The process ofaffmity purification was considered effective in regard to the removal 




As revealed by preliminary characterization by ELISA (Chapter 2), the 
antisera raised against angiotensin receptors contained anti-peptide antibodies that 
recognized native free AT1/AT2 receptor peptides with high titers. It remained to be 
determined whether the antisera could recognize the tissue native receptor protein. 
Since anti-peptide antibodies should recognize linear epitope on the antigen 
theoretically, proteins from various rat tissues were denatured with sodium dodecyl 
sulfate (SDS) and then separated by polyacrylamide gel electrophoresis (PAGE) on 
the basis of molecular weight. The separated proteins on the gel were electrically 
transferred onto nitrocellulose membrane (Western blotting) which retained their 
original spatial separation. After blotting, the membrane was probed with Thy-ATi 
antiserum. The signal was amplified with avidin-biotin peroxidase complex (ABC). 
3.2 METHODS 
3.2.1 Preparation of protein samples for SDS - PAGE 
Adult Sprague-Dawley rats (200-250g, from University's animal house) were 
killed by cervical dislocation. Tissues were isolated and cleared of surrounding fat 
and connective tissues. For the rat brain, only the CVO, thalamus and hypothalamus 
regions were isolated. For the rat heart, the ventricular halfwas used. Tissues («0.2g) 
were weighed and minced. The minced tissues were homogenized in 1ml 
homogenizing buffer (50mM Tris-HCl, lmM EDTA, lmM benzamidine, lmM 
PMSF, lmM DTT, pH7.4) using a polytron with maximum speed (Dremel). 
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The volumes of the homogenates were adjusted to 2ml with homogenizing 
buffer (pH.7.4) and centrifuged at 600xg for 5 minutes at 4°C with a table-top 
refrigerated centrifuge ^ppendorf). The supernatant was further centrifuged at 
15000xg for 30 minutes at 4°C to obtain membrane proteins. The pellets were then 
resuspended in 100mM Tris-HCl buffer (pU7A) by drawing up and down several 
times with a 1ml syringe (Terumo). An equal volume of 2X sample loading buffer 
(20% glycerol, 4% SDS, 25^ig/ml bromophenol Blue, 125mM Tris-HCl, 1% 2-
mercaptoethanol) was added to solubilize the proteins. The mixture was boiled for 5 
minutes, and lOOjug protein of each tissue was then subjected to SDS-PAGE. 
3.2.2 Protein determination 
Protein concentration of tissues resuspended in sample loading buffer was 
determined by a modified method ofLowry (Peterson, 1977). Distilled water (900jid) 
was added to 100 i^l of appropriately diluted sample. 0.15% sodium deoxycholate 
(DOC) and ice-cold 72% TCA, each 100 jul, were then added. The mixture was 
vortexed and left in ice-water bath for 30 minutes. Precipitated protein was spun 
down at 15000xg and the pellet was redissolved in 1ml reagent A ( 2% Na2CO3, 
0.02% CuSO4, 0.04% K-Na Tartrate). After 10 minutes of incubation at room 
temperature, lN Folin reagent (100 fil) was added and mixed vigorously at once. 
After 30 minutes of incubation at room temperature, protein concentration was 
determined by measuring the absorbance at 750nm. BSA (Fraction V; 98-99% 
purity) (Sigma) was used as the protein standard. 
3.2.3 SDS-PAGE 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed as 
described by Laemmli (1970). 5% stacking gel and 12.5% separating gel were used. 
100 ^g ofeach tissue sample was loaded. Prestained protein markers (New England 
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BioLabs) were used as molecular weight standards. The gel was run at 60V 
ovemight ( « 12-15 hrs) using a Vertical Slab Unit (Hoefer). 
3.2.4 Western Blot 
Proteins on the polyacrylamide gel were electro-transferred onto 
nitrocellulose membrane (Schleicher & Schuell，O.l^m) at 4°C as described by 
Towbin and co-workers (1979). Protein transfer was performed at 70 V for 3 hours 
at 4°C. 
3.2.5 ImmunobIotting 
The nitrocellulose membrane was incubated in an immunoblotting buffer 
(50mM Tris-HCl, 80mM NaCl, 0.02% NaN3, 5% dry skimmed milk, 2mM CaCl2, 
pH7.4) for 1 hour at room temperature to saturate unoccupied binding sites for 
protein on the membrane. The membrane was first washed with DPBS, and was then 
incubated with a solution of avidin DH (50^1 in 10ml DPBS, pH7.4) (Vector) for 
one hour. After washing in DPBS, the membrane was incubated with d-biotin 
(O.lmg/ml) (Sigma) for one hour to saturate bindings sites for biotin on the blot. 
Unbound biotin was removed by washing with three changes of 20ml 
immunoblotting buffer at 5 minute intervals. The blot was then exposed to 
appropriately diluted crude Thy-AT! antiserum (lOml) in the immunoblotting buffer 
ovemight (« 15-20 hrs) at room temperature. 
Unbound antibodies were removed by washing with the immunoblotting 
buffer. Bound antibodies were detected using the Avidin-Biotinylated Peroxidase 
Complex (ABC) method (Vector) (Hayat, 1993). The blot was incubated in 
biotinylated goat anti-rabbit IgG antibody C^ector Laboratories) (1:1000 in 
immunoblotting buffer) at room temperature for 2 hours. After washing with DPBS, 
the membrane was further incubated with an avidin-biotinylated peroxidase complex 
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(ABC complex) (50^1 avidin DH and 50 i^l biotinylated peroxidase in 10ml DPBS) 
for 30 minutes at room temperature as suggested by the manufacturer. 3,3'-
Diaminobenzidine (DAB) (Sigma) was used as the substrate for peroxidase (Sunmer, 
1988). Color reaction was intensified with cobalt chloride (0.70mM DAB, 21mM 
cobalt chloride, 0.02% H2O2 in distilled water) (Hayat, 1993). The reaction was 
terminated by washing the nitrocellulose membrane in distilled water. Finally, the 
nitrocellulose membrane was dried between pieces offilter paper. 
Simultaneously, membranes with blotted proteins were also incubated with 
normal rabbit serum or antiserum pre-absorbed with AT! peptides immobilized onto 
gel matrix. 
3.3 RESULTS 
The nitrocellulose membranes were incubated with Thy-ATi antibodies. 
Upon visualization by peroxidase-DAB reaction, 3 distinct bands were consistently 
observed. The corresponding molecular weights were 40，70 and 124 kDa as 
estimated with reference to the standard marker proteins (Fig. 3.1a). The intensity of 
these bands was significantly reduced when the antibodies were preabsorbed with 
immobilized ATi peptides (Fig. 3.1b). There was no band visible when the 
membrane was incubated with normal rabbit serum (Fig. 3.1c). 
The 40-kDa band was only present in rat brain, heart, kidney and adrenal. 
The 70-kDa was present in all the tissues tested, while the 124-kDa band was present 
in only some of the tissues. (Fig. 3.1a). 
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Fig- 3.1 Nitrocellulose membrane with blotted proteins from various rat tissues. 
The membranes were incubated with (a) Thy-AT! antiserum; (b) preabsorbed Thy-
ATi antiserum; (c) normal rabbit serum. The antisera were diluted at 1 : 2000. Three 
immunoreactive bands with molecular weights of 40, 70 and 124 kDa respectively 
were noted. Molecular weight reference proteins included: MBP-P-galactosidase 
(175,000)，MBP-paramyosin (83,000)，glutamic dehydrogenase (62,000), aldolase 
(47,500), triosephosphate isomerase (32,500), p-lactoglobulin A (25,000) and 
lysozyme (16,500). 
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3.4 DISCUSSIONS 
SDS-PAGE followed by immunoblotting with Thy-ATi antiserum revealed a 
distinctive pattem of protein bands as compared with other blotted with normal 
rabbit serum. 
Three proteins with molecular weights of 40，70 and 124 kDa respectively 
were consistently stained (Fig.3.1), and thus were specifically bound with Thy-ATi 
antiserum. These proteins represented potential candidates for rat ATi receptor. In 
fact, proteins of similar molecular weights have been reported to bind radiolabelled 
angiotensin E in various studies. Capponi and Catt (1980) reported that 
solubilization of photoaffinity-labelled angiotensin binding sites in rat adrenal cortex 
& uterus resulted in two proteins of 126 and 64.5 kDa respectively. By covalent 
cross-linking, angiotensin receptors with apparent molecular masses of 68 kDa 
(Soffer, 1983) and 63 kDa (Guillemette et al., 1986) have been found. The 
molecular mass value of 124 kDa found in the present study is slightly higher than 
that (116 kDa) observed by Paglin & Jamison (1982) after disuccinimidyl suberate 
cross-linking of ATi receptors labelled with 仍1- AngH of rat adrenal membranes. 
These variations in molecular mass values might be explained by the different 
molecular standards used for molecular weight estimation. Alternatively, these 
variations might be resulted from different post-translational modification, and/or 
different AT! receptor subtypes expressed in different cell types or different animal 
species. It should also be emphasized that the molecular masses obtained from 
prestained standard protein markers are only approximations. 
The 40-kDa band was particularly of interest because this molecular weight 
value agreed very well with that suggested by Murphy & coworkers (1991). They 
isolated a cDNA encoding the rat vascular AT! receptor which corresponded to a 
protein of40889 Da when translated. Therefore, the 40-kDa protein was likely to be 
an ATi receptor. Moreover, results from cDNA cloning ofATi had suggested that 
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the receptor protein contained several possible glycosylation sites (Murphy et al., 
1991). The 70-kDa and 124-kDa proteins might represent glycosylated forms of 
ATi. The multiple bands with molecular weights around 70 kDa might be the result 
of different degrees of glycosylation. 
The distribution pattern of the 40-kDa band also provided further support to 
its identity as an ATi receptor because it was selectively distributed in tissues that 
had been well known to be target tissues of angiotensins, namely brain (Phillips, 
1987)，heart (Whitebread et al., 1989)，kidney (Clark et al, 1991) and adrenal 
(Whitebread et al., 1989). In fact, ATi-specific antagonists have been shown to 
inhibit the physiological effects of angiotensin E on these tissues. Decreases in renal 
artery blood flow, urine output, filtration rate and sodium excretion induced by Ang 
n in kidney were also blocked by ATi-antagonists (Clark et al., 1991). Functional 
antagonism was demonstrated by blockade of Angn-induced ^^ Ca^ ^ efflux in rat 
aortic smooth muscle cells and of Ang E-induced contraction in rabbit aorta by 
losartan (Timmermans et al., 1991;Wong et al., 1991). 
It has been noted that the intensity of the 40-kDa immunoreactive-band 
present in liver was variable in separate experiments, ranging from non-detectable to 
barely detectable. However, liver was well known to contain ATi receptors. For 
example, in isolated rat hepatocytes, Ang E induced an increase in the expression of 
c-/oy, c-myc, c-mos, as well as P-actin, and this effect was inhibited by losartan 
(Gonzalez-Espinosa & Garcia-Sainz, 1992). A possible reason for this inconsistency 
might lie in the sensitivity limit in the detection ofthe 40-kDa band. Alternatively, 
the major functional form of ATi in liver might be glycosylated, represented by the 
70-kDa bands. 
It was also noted that the 40-kDa band was consistently absent from rat 
pancreas which had never been reported to have any angiotensin response. However, 
the 70-kDa band, a putative glycosylated form of ATi receptor, was present in 
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pancreas. The possible relationship between these immunoreactive proteins and 
pancreatic sensitivity to angiotensin was investigated in Chapter 4. 
Testing of false positive reactions was performed by incubation with either 
normal serum, omission of primary and secondary antibodies or incubation with 
Thy-ATi antiserum preabsorbed with ATi peptide conjugated to gel matrix. No 
staining was observed when normal rabbit serum was used (Fig. 3.1c). Negative 
result was obtained when both first and second antibodies were omitted. The 
intensity of the bands were substantially lower when the membrane was incubated 
with preabsorbed ATi antiserum compared with crude ATi antiserum (Fig. 3.1a and 
3.1b). Theoretically, all specific ATi antibodies were removed from the antiserum by 
binding to the immobilized ATi antigen (immunoadsorption), leaving the 
preabsorbed antiserum devoid of specific ATi antibody. However, complete removal 
might not be achieved in the case. A small amount of specific AT! antibody might 
remained in the preabsorbed antiserum, which could account for the existing but 
fainter bands observed. 
In conclusion, the bands specific for the Thy-ATi antibodies might 
correspond to different forms of rat ATi receptor. However, it should be noted that 
the peptide chosen against which the antibodies were raised is common to both ATiA 
and ATiB in amino acid sequences, so both ATiA and ATiB could have been 




Lmnunoblotting experiments revealed three distinct ATi -immunoreactive 
bands with molecular weights of approximately 40，70 and 124 kDa respectively 
(Fig.3.1a). The 40-kDa band selectively distributed in tissues that were known to be 
angiotensin-responsive. In rat pancreas, the lack of the 40-kDa band was noted. 
There has been no report of any physiological effect ofangiotensin H in rat pancreas. 
However, the 70-kDa bands, putative glycosylated forms ofATi, was present. These 
observations led us to investigate whether rat pancreas is sensitive to angiotensin K 
The responsiveness of rat pancreas to Ang H was evaluated by assaying the release 
ofa-amylase under Ang H stimulation. 
The pancreas secrets ajuice having two major components, an alkaline fluid 
and enzymes (Davenport, 1982). The alkaline fluid components has a high 
concentration of bicarbonate, which neutralizes acid entering the duodenum and 
helps to regulate the pH of intestinal contents. The enzyme component contains 
three major enzyme groups: amylolytic, lipolytic, and proteolytic. Most enzymes are 
secreted in multiple forms as isoenzymes. 
a-amylase (E.C.3.2.1.1; 1,4-a-D-glucan glucanohydrolase) (Vonk & 
Western, 1984) is an endoglucosidase that cleaves the a-l,4-glucosidic bond ofthe 
substrate at internal positions to yield dextrins and oligosaccharides with the C]-OH 
in the a configuration. The a-l,6-glucosidic bonds are not split (Wong, 1995). An 
a-1,4 linkage neighboring an a-1,6 branching point in the substrate is resistant to 
attack by the enzyme (Whitaker, 1994). The products of digestion of a branched 
starch are glucose, maltose, maltotriose, and a mixture of dextrins containing a-l,6_ 
branches, a-amylase is secreted in thejuice in an active state. The enzyme is stable 
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in the pH range 4-11, and its pH optimum is 6.9. It requires Ca]+ for stability and 
activity (Whitaker, 1994). 
Based on the facts that angiotensin was known to stimulate Ca�+ mobilization 
in various tissues (Capponi et al., 1984; Gunther, 1984; Alexander et al., 1985; 
Brock et al., 1985; Kawahara et al, 1988) and that amylase secretion was triggered 
by a rise in intracellular Ca�+ levels in acinar cells (Grapengiesser et al, 1989)，it is 
reasoned that angiotensin response in pancreas can be assessed by measuring the 
amylase secretory response, ln the present study, the effect of angiotensin H on 
pancreatic secretion of a-amylase was compared to that ofknown secretogogues of 
a-amylase, namely cholecystokinin, acetylcholine and carbachol. Cholecystokinin 
(CCK) and acetylcholine (ACh) are two primary stimuli of pancreatic enzyme 
secretion (Duthie & Wormsley，1979; Wong, 1995). Cholecystokinin (or 
pancreozymin) is released from APUD cells in the mucosa by digestion products in 
the duodenal lumen. Acetylcholine is released by the vagal nerve endings in the 
pancreas. The vagus is stimulated during the cephalic phase of digestion by the 
perception of food. Carbachol (Carbamycholine) is a related stable analogues of 
acetylcholine (Semka &Jacobson, 1983). 
4.2 METHODS 
4.2.1 Perfusion of Pancreas 
Adult Sprague-Dawley rats (200-250g, from University's animal house) were 
killed by cervical dislocation. The pancreas was isolated. It was freed ofsurrounding 
fat，connective tissues and blood vessels, and was then minced into small pieces. 
They were weighed, and approximately 0.2g oftissue was used for each perfusion 
channel. 
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2.5ml-syringes (Terumo) were used as perfusion chambers, which were 
immersed in a 37°C water-bath. The lower end of the syringe was connected to a 
peristalic pump (ATTA). The pump was in turn connected to a fraction collector 
(Pharmacia Biotech). A layer of 500mg Sephadex G-25 gel (in 1ml distilled water) 
(Sigma) was placed on top of a filter paper at the bottom ofeach perfusion chamber. 
Each perfusion chamber contained minced pancreas in 0.25ml perfusion 
medium (118mM NaCl; 4.7mM KC1; 1.16mM MgCl2; 1.16mM NaH2PO4; 25mM 
HEPES; 0.2% BSA; 8mg/ml glucose; 2.0mM CaCl2). To avoid enzymatic 
degradation ofpeptides tested, soyabean trypsin inhibitor (Sigma) was added into the 
medium at a concentration of 0.02mgy'ml. The presence of trypsin inhibitor in the 
perfusion medium also protects the pancreas against autodigestion by small amounts 
oftrypsin that may become active within it. 
The perfusion rate was adjusted to 0.5ml/min, one fraction was collected 
every 2 minutes. The tissue in the chamber was allowed to equilibrate by perfusing 
with the medium at 3>TC for 1 hour. Perfusion medium containing AngH (10 ^M), 
acetylcholine (ACh) (10 ^M), carbachol (10 i^M), or cholecystokinin (CCK) (lnM) 
was applied to the tissue for four minutes at the tenth minute. The time delays from 
the pump to the perfusion chamber and that from the chamber to the fraction 
collector were both 2 minutes. The effect ofthe drugs on the stimulated a-amylase 
release response was reflected in the fractions collected from the fourteenth to the 
eighteenth minutes. Average of the amylase content of the second to the fifth 
fractions was defmed as basal secretion. Fractions were collected in 1.5ml microfuge 
tube for a period of 80 minutes. Totally 40 fractions were collected. 
At the end ofevery perfusion experiment, the tissues used were homogenized 
using a 1ml all-glass homogenizer (Wheaton). The suspension was then centrifuged 
at 15,000xg for 15 minutes. The supernatant was saved for amylase activity assay in 
order to calculate the total amount of amylase activity ofthe tissues. 
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4.2.2 Assay of Amylase Activity 
Samples from fractions collected were diluted 50 folds and tissue 
supematants were diluted at 1:50,000. Amylose azure (Sigma) was used as substrate 
for a-amylase. Amylose azure is potato amylose covalently linked with Remazol 
Brilliant Blue R (Rinderknecht et al., 1967). Since the amylose fraction contains 
only a-1,4 glucosidic linkages, a-amylase should hydrolyze it completely to maltose. 
However, some maltotriose usually remains ^Vhitaker, 1994). 
Amylase azure (1% , 250^il) was added to an equal volume of samples in 
microfuge tubes. The mixture was incubated in 37®C for 30 minutes. Acetic acid 
(6%, 500|ul) was then added to the reaction mixture to stop the reaction. The 
microfuge tubes were centrifuged at 10,000xg for 5 minutes. Absorbance of the 
supematants were read at 595nm. Standard curve of amylase activity was 
constructed using porcine a-amylase (Sigma). 
4.2.3. Calculations 
Readings of absorbance at 595nm were converted to a-amylase 
concentration (unit/ml) by a linear regression method using the data from standard 
a-amylase assay. One unit of a-amylase liberates 1.8mg of maltose from starch in 
3min at pH6.9 at 20°C as defmed by the manufacturer (Sigma). 
Reading from tissue supernatant was taken as total amylase content (U); peak 
amylase release G /^ml) corresponded to the highest value in one single experiment; 
basal amylase release (U/ml) = average of amylase release (U/ml) from the 2nd to 
the 5th fractions ； rate of amylase release = amylase release 0^/ml) / basal amylase 
release (U/ml) X 100% . 
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4.3 RESULTS 
The basal amylase release (U/ml) related directly with total amylase content 
(U), suggesting a steady constituted amylase release from pancreas (Fig. 4.1). 
Moreover, the peak amylase release (U/ml) was proportionately related to basal 
amylase release (U/ml) (Fig. 4.2). Hence, amylase release (U/ml) was normalized 
with basal amylase release (U/ml) to obtain rate of amylase release so that their 
values could be compared between experiments. 
In control experiments, the tissue was perfused with only perfusion medium 
throughout the experiment. Both acetylcholine and carbachol potentiated the basal 
secretion ofa-amylase at a concentration of lOjuM，while CCK, at lnM, produced a 
even more pronounced potentiating effect (Fig. 4.3). On the contrary, the presence of 
Angn (lOfiM) did not enhance the secretion of a-amylase from rat pancreas as 
compared with the secretion pattern in positive-control experiments. This lack of 
response to Ang H was also indicated by the apparent overlapping of the Ang U 
response curve with the control curve. 
4.4 DISCUSSIONS 
As an attempt to evaluate the sensitivity of rat pancreas to Ang n, the effect 
ofAngH on pancreatic a-amylase release was studied. The relationship between the 
peak and basal and total amylase release was depicted by Fig. 4.1 and Fig. 4.2. It was 
shown that basal amylase release related roughly linearly with total amylase content 
(Fig. 4.1). This indicated that the amount of total amylase content in the pancreas 
was one of the factors that affected the rate of amylase release. Since the total 
amylase content in each pancreas used varied from experiment to experiment, the 
data in amylase release 0^/ml) must be normalized so that rate of amylase release 
could be compared across different experiments. 
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Fig. 4.1 Relationship between basal amylase release 0^/ml) and total amylase 
content (U). Basal amylase release was taken as the average of the readings fi:om the 
second to the fifth fractions. Total amylase content was obtained fi:om assay of 
amylase activity in tissue homogenate of pancreas after each perfusion experiment. 
Data were from 30 different perfusion experiments including ones with angiotensin 
n, acetylcholine, cholecystokinin or carbachol added and control ones. One unit (U) 





































































































Fig. 4.2 Relationship between peak amylase release (U/ml) and basal amylase 
release (U/ml). Peak amylase release was taken as the highest reading within a single 
perfusion experiment. Basal amylase release was taken as the average of the readings 
from the second to the fifth fraction. Data were from 30 different perfusion 
experiments including ones with angiotensin E, acetylcholine, cholecystokinin or 
carbachol added and control ones. One unit (U) liberates 1.8mg of maltose from 





































































































Fig. 4.3 Sensitivity ofpancreatic a-amylase release to AngH (lO^M), CCK (lnM), 
ACh (lO^M), and carbachol (lO i^M). The perfusion rate was adjusted to 0.5ml/min. 
lml-fractions were collected every 2 minutes. The isolated pancreas was perfused 
with various testing chemicals in the perfusion chamber between the 14th and 18th 
minutes ( _ ). The results were means of 6 separate experiments for each testing 
chemical or control. For clarity, the error bars were omitted from the graph, and the 










































































It was also shown that peak amylase release (U/ml) related directly to basal 
amylase release 0^/ml) (Fig. 4.2). Therefore, it was justified to normalize the data 
values with respect to basal amylase release in order to eliminate the effect of 
varying total amylase contents in different experiments. 
Fig. 4.3 shows the time course of the effect of ACh, CCK, carbachol and 
Angn on a-amylase release from the isolated pancreas. Ang E (lOjuM) was added at 
the tenth minute after 1 hour of equilibration. The level of pancreatic a-amylase 
released in response to AngE almost coincided with the control level. On the 
contrary, the presence of CCK (lnM), ACh (lO^iM) and carbachol (10|uM) resulted 
in rapid bursts ofa-amylase release from pancreas. 
Significant a-amylase release occurred within 10 minutes. Carbachol, being 
a more stable related analog of acetylcholine, resulted in a more sustained effect on 
a-amylase release. CCK at lnM was even more potent than carbachol (lOjuM) in 
stimulating release of a-amylase. 
Cholecystokinin is the major physiological stimulant for secretion of 
enzymes by the acinar cells (Davenport, 1982). For experimental work, a commonly 
used stimulant is the synthetic C-terminal octapeptide of cholecystokinin designated 
CCK-8，which was employed in the present experiment. Cholecytokinin and 
acetylcholine depolarize acinar cell membrane and uncouple it from neighboring 
cells. They release bound calcium from the cell membrane and permit entry of 
calcium from extracellular fluid which then triggers the release of enzymes 
(Davenport, 1982; Soipchuk et al., 1989). 
Since release of a-amylase was observed with ACh, CCK and carbachol but 
not with AngH, these positive controls showed that the insensitivity ofpancreatic a-
amylase release to Ang H was not due to the protocol employed. There was a gradual 
increase ofamylase release, especially when the tissue was stimulated with CCK and 
72 
carbachol. This might be due to the disintegration of cell membrane of pancreatic 
cells which consequently resulted in complete release of a-amylase from cells. The 
long-lasting nature of the drugs or the existence of residual drugs in the perfusion 
chambers might also account for the pulse release ofamylase. 
As shown by the results from Western blot (Fig. 3.1)，the 40-kDa ATi -
specific band was missing from the pancreas. In accord with the lack of report 
concerning the physiological effect of Ang E in rat pancreas, the present observation 
confirmed the lack of angiotensin response in rat pancreas. These results lent 
considerable support to the notion that the 40-kDa protein band may be a type-1 
angiotensin receptor protein. However, the results from the present experiment do 
not suggest that the 40-kDa ATi -immunoreactive band is necessarily a functional 
ATi receptor. 
Despite the absence of the 40-kDa band, 70-kDa bands were present in rat 
pancreas. If these bands really represented glycosylated forms of AT! receptor as 
discussed in Chapter 3，it will be of interest to investigate this presence of 
angiotensin receptor despite the lack of angiotensin response in rat pancreas. A 
possible approach to address the above paradox is to carry out deglycosylation of 
proteins before subject to SDS-PAGE. This will reveal whether the 70-kDa proteins 





Regional distribution of ATi and AT2 receptors has been defmed by 
competitive receptor autoradiography and pharmacological means. In general, ATi 
exhibits a broad receptor distribution in all tissues, while AT2 is found in fewer 
areas. Although the distribution of AT2 in rats did not provide definitive clues to 
their physiological function, the exclusive predominance 0fAT2 in adult rat adrenal 
medulla and uterus (Whitebread, 1989)，ovarian granulosa cell (Pucell et al., 1991)， 
cerebellum (Gehlert et al., 1991)，fetal rat skin and skeletal muscle (Feuillan et al., 
1993) is still ofprincipal interest. Recently, heterogeneity among AT2 receptor has 
been reported. The AT2a subtype is sensitive to guanine nucleotides and pertussis 
toxin in a manner similar to some G-protein linked receptors. The AT2b subtype is 
insensitive to guanine nucleotides (Bottari et al., 1991) and pertussis toxin (Tsutsumi 
and Saavedra, 1992). 
With the AT2 antibodies available, it was possible to use the technique of 
immunohistochemistry to visualize AT2 receptors precisely. Histochemistry offers 
the only methods by which chemical components of tissues can be localized 
regionally within a particular tissue or at a cellular or subcellular level (Troyer, 
1980a). Rat adrenal glands were chosen as the subject of study because they were 
well known to contain both ATi and AT2 types of angiotensin receptors as revealed 
by autoradiographic studies (Chiu et al., 1989a). The adrenal glands are divided into 
a head, body and tail, from inferomedial to superior aspects (Cryer, 1992). The outer 
yellow cortex surrounds the pale grey medulla. Adrenal medulla accounts for about 
10% ofthe adrenal weight. In some areas, the border between the cortex and medulla 
is sharp, but in others, there is a less well-defined margin, with some intermingling 
of the two. 
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The cortex is divided into three zones, each with characteristic light 
microscopic and ultrastructural features. The zona glomemlosa consists of 
discontinuous subcapsular aggregates of small cells with a high nuclear-to-
cytoplasmic ratio and few lipid droplets. The major part comprises the zona 
fasciculata, with large lipid-laden or clear cells arranged in columns between the 
glomemlosa and the inner zona reticularis. 
The rat adrenal medulla comprises mainly the chromaffin cells, or 
pheochromocytes which become dark brown when fixed in chrome salts (Hillarp & 
Hokfelt, 1955). The medulla, which is specialized in the production and release of 
catecholamines, was particularly suitable for the present study because AT2 receptors 
are highly localized in this area (Chiu et al., 1989a; Chang & Lotti，1990; Balla et 
al., 1991). Furthermore, cDNA of AT2 receptor was cloned from an adrenal 
chromaffin cell line, PC12w ^Cambayashi et al., 1993 )• 
5.2 METHODS 
5.2.1 Preparation of sections 
Adult Sprague-Dawley rats (200-250g, from University's animal house) were 
killed by cervical dislocation. Adrenal glands were removed immediately, and were 
freed of surrounding fat and connective tissues. The adrenals were embedded in 
Tissue Tek O.C.T. embedding medium (Miles Scientific Co.), and freeze-frozen 
rapidly in liquid nitrogen. Frozen adrenal blocks were cut into serial sections of 
12|im in thickness with a Microm cryostat and thaw-mounted onto gelatinized glass 
microscopic slides (Raymond A Lamb-laboratories). 
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5.2.2. Light-Microscopic Immunohistochemical Study 
Sections were air-dried at room temperature ovemight. They were then fixed 
with 4% paraformaldehyde in phosphate-buffered saline (PBS, pH7.0) for 30 
minutes at room temperature. Sections were then washed in PBS containing 0.1% 
Triton-X 100 (TPBS, pH 7.0) and subsequently treated with 1% normal goat serum 
(DAKO) in TPBS at 4 ¾ ovemight to block non-specific Ig binding sites on the 
sections. After 2 washings with TPBS, the sections were exposed for 36-48 hours at 
4°C to affmity purified Thy-AT2 antibodies, diluted at 1:5 with PBS containing 1% 
normal goat serum and 0.1% Triton-X 100. Unbound antibodies were removed by 2 
washings with TPBS . 
Sections were then incubated for 2 hours in peroxidase-conjugated goat anti-
rabbit IgG antibody (DAKO), diluted at 1:200 with PBS containing 1% normal goat 
serum and 0.1% Triton-X 100. Having been washed twice with TPBS, the sites of 
antigen-antibody reaction were visualized with a mixture of 0.5mg/ml 3，3，-
diaminobenzidine (DAB), lOmM imidazole and 0.03% H2O2 in 100mM Tris-HCl 
^)H 7.4). The specificity ofthe immunoreactions was checked by substitution ofthe 
primary antibody with normal rabbit serum (1:2000), or by co-incubating purified 
Thy-AT2 antibodies with AT2 peptides (lOmg/ml). Following immunohistochemical 
staining, sections on the slides were covered with a cover-slip in a mixture of 
glycerol: water (3:1) and examined with a light microscope. 
5.3 RESULTS 
As a result of the treatments with purified AT2 antibodies, the chromaffin 
cells in the adrenal medulla became colored so that they could be visualized by light 
microscopy. The adrenal medulla examined showed a large number of AT2-
immunoreactive cells (Fig. 5.1a). The whole medullary area was uniformly stained. 
76 
Most of the AT2-immun0reactive cells were uniformly stained but not the nucleus of 
the chromaffin cells. On the contrary, the cortical cells were unstained. 
Jn the control sections, normal rabbit serum was incubated instead of Thy-
AT2 antibodies. All the medullary cells and cortical cells were clearly unstained, or 
exhibited a faint brownish staining comparable to the background. (Fig. 5.1b) 
The most dramatic feature observed in this study was the occurrence ofcords 
ofstained cells occasionally appeared across the cortical area (Fig. 5.2a). The cord of 
cells extended from the corticomedullary boundary through zona reticularis and zona 
fasciculata to zona glomerulosa (Fig. 5.2b). These stained cells in the adrenal cortex 
existed as scattered clusters in other separated experiments (Fig. 5.3a and 5.3b). No 
such cord or cluster of stained cells is found in the capsular layer in any of the 
sections stained. 
5.4 DISCUSSIONS 
The sites of immunoreactivity towards AT2 antiserum in the tissue are 
detected histochemically, by means of the DAB-hydrogen peroxide reaction. 
Lmnunohistochemical study of the rat adrenal gland showed the presence of AT2-
immunoreactive cells in the adrenal medulla. The positive staining result obtained 
suggested either that the desired substrate, AT2, was present in the adrenal medulla, 
or that other substrates were being stained, or that the staining result was an 
nonspecified deposit, unrelated to any substrate. 
Testing of false positive reactions was performed by incubation with normal 
rabbit serum. The lack of immunoreactivity in sections incubated with normal rabbit 
serum illustrated the specificity of the anti-AT2 antibodies. It was also possible that 
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Fig. 5 .1 Photomicrography showing a transverse section of a rat adrenal gIand. 
(a) The section was stained umnunohistochemicany using antisera to Thy-AT2 . t i the 
meduEa (M), a strong signal was detected; in the cortex (C), no kbeHng was seen. 
Affinity purified antibodies were used at 5 fold dilution, wfaich corresponds to 
approximately 13,000 fold dilution of crude Thy-AT2 antiserum. (Scale = lOO^m) 
(b) An adjacent section was stained innnunohistochemicany using nonmI rabbit 
serum (2000 fold dilution). No staining was observed throughout the whole giand. 
(Scale = lOOjim) 
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Fig. 5.2 Photomicrography showing a transverse section of a rat adrenal gland, 
(a) The section was stained immunohistochemicaUy using antisera to Thy-AT2 . Jn. the 
meduUa (M), a strong signal was detected; in the cortex (C), a cord of ceUs across 
the cortical area was cleariy visible as brown stain. The cord of ceUs extended from 
the corticomeduHary boundary to zona glomenilosa. Affinity purified antibodies were 
used at 5 fold dilution, which corresponds to approximately 13,000 fold dilution of 
crude Thy-AT2 antiserum. (Scale = lOO^m) (b) A cord of stained ceUs extended into 
zona glomerulosa. No staining was observed in the capsular layer (Y). (Scale = 
25pm) 
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Fig. 5.3 Photomicrography showing a transverse section of a rat adrenal gIand. 
(a) The section was stained immunohistochemicaUy using antisera to Thy-AT2 . Li the 
meduUa QA^ a strong signal was detected; in the cortex (C), clusters of ceUs across 
the cordcaI area was clearly visible as brown stain. Affinity purified antibodies were 
used at 5 fold dilution, which corresponds to approximately 13,000 fold dilution of 
crude Thy-AT2 antiserum. (Scale = l O O ^ u n ) � The immunoreactive ceHs appeared 
as distinct dusters intensely stained. (Scale = 50pn) 
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diffusion, either of substrate or qf reaction product, might result in the staining of 
sites which were not the original in vivo site of the substrate, thus accounting for the 
occasional immunostaining in adrenal cortex. However, genuine localization was 
likely to be present in the tissue preparation because the positive result was shown in 
clearly defmed structures, not surrounded by blurred areas of staining. 
Note that in addition to the use of affmity-purified antibodies, Triton-X 100 
was added to the incubation and washing buffers so as to minimize background 
staining. The sections were also pre-incubated with normal goat serum to block non-
specific adhesion. 
The present regime used for fixation of the sections were found to be optimal 
for the present study after repeated trials with different types of fixatives and 
different durations of fixation. Glutaraldedyde (3%) and methanol were found to be 
less than satisfactory in terms of the intensity of staining resulted. Moreover, poor 
morphology was resulted from exposure time longer than 60 minutes to 
paraformaldehyde, and poor staining was obtained if fixation was longer than 45 
minutes. 
Most of the chromaffin cells were positively stained with purified AT2-
antibodies. However, the adrenal cortical area remained unstained. These 
observations of AT2-immun0reactive cells in rat adrenal gland are generally in 
agreement with earlier descriptions about autoradiographic localization of AT2 
receptors in rat adrenals (Chiu et al., 1989a). Using the nonpeptide antagonist 
EXP655 which was specific for AT2, they showed that over 90% of the Ang H-
binding sites in the rat adrenal medulla were sensitive to EXP655 and thus belonged 
to the AT2 class of AH receptors. They also showed that in the adrenal cortical area, 
80% of the total angiotensin binding could be inhibited by DuP 753, which was an 
ATi specific antagonist. The staining pattern obtained with the Thy-AT2 antiserum 
agreed with the widely reported ones and the antiserum also showed high specificity 
in competitive ELISA. Furthermore, the sequence of the AT2 peptide used to raise 
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antibodies was found to match with only the cloned AT2 receptor when searched 
through the protein databases (GeneBank, PDB, Swiss Prot and FJR) with a Blastp 
program ofNCBI. Hence, the immunoreactivity obtained should correspond to AT2 
receptor. 
A striking feature of the antibodies-treated adrenal gland, as shown by light 
microscopy, was the presence of cords of stained cells across the unstained cortical 
area. Li the rat, there is good evidence that proliferation of adrenocortical cells 
occurs mainly in the outer fasciculata with a migration of cells into the glomerulosa 
and fasciculata/reticularis (Cryer, 1992). It was observed that the cords of cells 
extended from the inner zona reticularis through zona fasciculata to zona 
glomerulosa (Fig. 5.2a and 5.2b). It was known that AT2 was abundantly and widely 
expressed in fetal tissues and immature brain in rats (Feuillan et al., 1993; Grady & 
Kalinyak, 1993). In fact, studies in neonatal rats indicated that many tissues that 
expressed fetal AT2 sites during early postnatal life significantly lowered or ablated 
the expression in adult (Feuillan et al., 1993). It was also suggested that Ang E-
mediated signal transduction was involved in the divergent differentiation of rat 
adrenocortical cells (Roskelley et al., 1992). It is possible that the cords of stained 
cells represented migrating differentiating cortical cells that express AT2 receptors 
transiently. Further experiments are needed to confirm the identity of these AT2 -
immunoreactive cortical cells. 
It was concluded that the AT2 antiserum collected from immunized rabbits 
could be used to localize AT2 in other tissues. However, the only way to confirm 
definitely the identity of the immunoreactive substances to the antiserum is to cany 
out immunoprecipitation followed by AngE binding assay with the precipitated 
product. 
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The physiological role of AT2 in adrenal medulla is unknown at present. AT2 
is probably involved in the regulation of catecholamine release since the chromaffin 
cells in adrenal medulla are specialized in catecholamine secretion. The adrenal 
(both from cats and bovine) is extremely sensitive to angiotensin in catecholamines 
release (Feldberg & Lewis, 1964; Powis & 0,Brien, 1991). Previous studies 
indicated that the effect of Ang H on catecholamine release was mediated by ATi 
receptor (Stachowiak et al., 1990; Wong et al., 1990) despite the predominance of 
AT2 receptor in adrenal medulla. Recently, Martineau and co-workers (1995) also 
demonstrated that a ATi-specific antagonist, BMS 186295, inhibited the Ang H-
induced increase in dog adrenal catecholamine release. However, BMS 186295 
failed to abolish the effect of Ang H. This suggested that AT2 may be partially 
involved in the catecholamine response to Ang E in adrenal. On the other hand 
adrenal cortex is specialized in the synthesis and release of steroids, including 
aldosterone. Ang E have been demonstrated to be a potent stimulator of aldosterone 
synthesis (Hughes & Roth，1971b). The general absence of AT2-immun0reactive 
cells in the adrenal cortex might serve as an evidence to exclude a role 0fAT2 in the 
regulation of aldosterone release. 
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CHAPTER 6 
The present study demonstrated the successful preparation of polyclonal 
peptide-directed antibodies against the two subtypes ofangiotensin receptor. Firstly, 
polyclonal antibodies were chosen instead of monoclonal ones as the subject ofthe 
study because polyclonal antiserum was the cheapest option and easiest to make. 
Nevertheless, polyclonal antisera also present the greatest risk ofcross-reaction with 
non-target antigens, not only with respect to the binding specificities of the 
constituent antibodies but also the ‘unknown，constituents ofthe serum, which may 
bind to the tissue and subsequently to the labeling reagents to give false positive. 
However, ifthe antiserum has been affmity purified and carefully characterized, its 
binding to many epitopes on a specific antigen will be an advantage in 
immunohistochemistry and will help to counteract the destructive effects the fixative 
may have on individual epitopes. Since it is unlikely for all epitopes to be destroyed 
by fixation, polyclonal antibodies offer the advantage of being able to recognize 
more than one epitope. Monoclonal antibodies, of course, can offer unique 
specificity but if that epitope is liable to damage during the fixative procedures, 
applicability of the monoclonal antibody will be limited. 
It should be emphasized that the careful choice ofpeptide sequence from the 
receptor protein was crucial to the production of immunohistochemically useful 
antibodies. Since electrostatic forces between oppositely charged ionic groups are 
important factors which hold an antigen and an antibody together, the peptides were 
chosen so as to include as much charged amino acid residues as possible. For 
example，the ATi peptide contained lysine, arginine, asparagine and aspartate, 
whereas the AT2 peptide chosen contained lysine, arginine, glutamine and glutamate. 
The composition ofpeptides chosen also included a variety ofdifferent amino acid 
residues，so that identity with other proteins could be minimized, t i fact, the peptide 
sequences have been compared for homology using a Blastp program with the Swiss 
Prot protein database. The only significant match found for AT1/AT2 peptides was 
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with the receptor itself, indicating high specificity of the peptide sequences for the 
AT1/AT2 receptors. Note that the peptides chosen located at the intracellular C-
terminal tail of the putative seven-transmembrane domain model of the receptors 
(Murphy et al., 1991). The C-terminal tail has been suggested to interact with 
various proteins, such as kinases, therefore it should be available to interact with 
antibodies. Although this obviously presents the problem of penetration of 
antibodies into tissues, it also offers the possibility of applying the antibodies in 
immunoprecipitations and functional perturbation studies in the future. If the 
antibodies bind to the extracellular domains of the receptors instead, the binding may 
hinder ligand binding which will be required in the detection of functional 
angiotensin receptor. 
Li fact, several groups have tried to prepare polyclonal antibodies against 
angiotensin receptors. Zelezna and co-workers (1992) attempt to prepare a 
polyclonal antibody against a synthetic peptide located at the putative extracellular 
N-terminal tail of ATi receptor protein. The antibody recognized protein bands of 
molecular weights of 70 and 90 kDa, but no application in immunohistochemistry 
was mentioned. Partially purified AT2 receptors from solubilized NlE-115 
membranes were used as an immunogen in the development ofpolyclonal antibodies 
(Reagan et al., 1993), which identified immunoreactive proteins o f l l O and 66 kDa 
in solubilized NlE-115 membranes. However, the antibody could not recognize 
cloned AT2 receptor protein (Fluharty et al., 1995). 
The applicability of peptide-directed Thy-ATi and Thy-AT2 antibodies in 
Westem blot and in immunohistochemical studies have been demonstrated in the 
present study. Another obvious advantage is that antibodies can be raised against 
different isoforms of AT1/AT2. Two structurally related ATi receptor isoforms 
(ATj^ and AT^g) have been identified in rat (Iwai & Inagami，1992a) and in mouse 
(Sasamura et al., 1992). Comparison of the amino acid sequences of these two 
subtypes reveals a high degree of sequence homology, indicating a 96% identity at 
the protein level. The differences between the two subtypes involve 17-18 amino 
85 
acid substitutions, of which 14 lie outside the transmembrane domains with most 
sequence changes found in the C-terminal portion of the molecule. These isoforms 
cannot be differentiated by their pharmacological properties or binding affinities. On 
the contrary, synthetic peptides can be made specific to each of the isoforms, and 
specific antibodies can then be raised accordingly. It will be valuable to study their 
distribution in various tissues which may in tum give hints as to the functional 
significance of each isoform. 
Most of our current knowledge about angiotensin receptors evolved mainly 
through pharmacological approaches using various inhibitors of the RAS. The 
differential distribution of angiotensin receptor subtypes was studied (Dudley et al., 
1990; Gehlert et al., 1990), mainly using either competitive radioligand membrane 
binding or quantitative autoradiography. Autoradiography preserves the anatomical 
and morphological organization of the tissue and is much more sensitive to local 
concentrations of sites on particular cells or organelles. In these studies, AngH 
receptors were characterized by displacement ofthe parent peptide with the selective 
Angn receptor ligands. The parent peptide used was usually radiolabelled with ^^ ¾. 
This presents considerable hazard to researchers. Lnmunohistochemical techniques 
are devoid of such danger, and yet are also extremely specific due to intrinsic 
specificity in the binding between antigens and antibodies. Moreover, 
immunohistochemistry allows the visualization of individual cells with distinct 
staining by microscopy. There is merit in studying the cellular and subcellular 
distribution pattem of a given chemical component of tissue since morphological 
heterogeneity between cells usually implies functional heterogeneity. 
The rat adrenal gland was chosen as the subject of immunohistochemical 
studies. The existence of an adrenal RAS has been well documented both in humans 
and in various animal species (Racz et al., 1992). The functional significance of 
adrenal RAS has been mostly related to the control of aldosterone production. In 
fact，stimuli such as a low-sodium or high-potassium diet or nephrectomy induce 
consistent changes of adrenal renin and aldosterone levels (Aguilera et al., 1980). Jn 
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addition, the AT! angiotensin subtype receptors are known to mediate aldosterone 
secretion from rat adrenal cortical cells (Chang & Lotti，1990; Wong et al.，1990; 
Balla et al., 1991; Hajnoczky et al., 1992). A high density 0fAT2 receptors localized 
in the rat adrenal medulla was demonstrated in the present study. However, the 
physiological significance of AT2 receptor in adrenal medulla is unclear. Since 
chromaffin cells are specialized in the synthesis ofcatecholamines, and Ang E was 
known to enhance catecholamine release from autonomic nervous system (Hughes & 
Roth, 1971a) as well as secretion of catecholamines from adrenals (Powis & 
0,Brien, 1991)，AT2 may be involved in the regulation ofthis chromaffin function. 
Functional perturbation studies with Thy>AT2 antibody may help to unravel the 
fimctional role of AT2 receptor in adrenal medulla cell. 
The paired adrenal medullae, enclosed within the adrenal cortices, are an 
integral component of the sympathochromaffm system. In addition to the adrenal 
medullae，the sympathochromaffm system includes the sympathetic nervous system 
(Cryer，1992). However, whereas the vast majority of sympathetic postganglionic 
neurons release the catecholamine noradrenaline, the adrenal medullae release 
adrenaline predominantly, although they also release some norepinephrine. 
Chromaffin cells, which are derived embryological from a precursor cell common to 
adrenomedullary cells and sympathetic postganglionic neurons, are widely 
distributed and intimately associated with sympathetic ganglia during fetal life 
(McNicol, 1992). However, most ofthese degenerate postnatally. The major clusters 
of surviving chromaffin cells comprise the adrenal medullae, although some extra-
adrenal chromaffin cells persist throughout adult life. It will be ofinterest to study 
whether the extra-adrenal chromaffin cells also express abundantly the AT2 receptor. 
Adrenomedullary chromaffin cells consist ofadrenaline-chromaffm cells and 
noradrenaline-chromaffin cells in many mammalian species. However, proportions 
and distribution patterns of these two types ofchromaffm cells show marked species 
differences. Adrenaline-secreting cells contain granules that show only low electron-
density; noradrenaline-secreting cells contain intensely electron-dense granules 
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(Coupland et aL, 1964; Giynszpan^Winograd, 1975). The formation of adrenaline 
from noradrenaline is catalyzed by phenylethanolamine 7V-methyltransferase 
(PNMT; EC 2.1.1.28.; 5'-adenosyl-L-methionine: phenylethanolamine N-
methyltransferase) which transfers the ^-methyl group from ^-adenosylmethionine to 
the primary nitrogen group of noradrenaline. In mammals, PNMT is almost 
exclusively localized in the adrenal medulla (Kirshner, 1975). This enzyme has 
proven a useful marker for cells of adrenergic (as distinct from noradrenergic) 
phenotype. Jn bovine adrenals, the adrenaline cells located preferentially towards the 
outer margins of the medulla and the noradrenaline cells more towards the central 
lobular vein. This differential distribution provides the opportunity to determine 
whether adrenal Ang H receptors are associated with a particular cell type. 
Noradrenaline cells in adrenal medulla could be made visible by means ofglyoxylic 
acid histofluorescence (Tramezzani et al., 1964; Bjorklund et al., 1972; Watson & 
Barchas，1977; Kieman, 1981). Reaction ofglyoxylic acid with noradrenaline leads 
to the development of fluorophore on tissue sections (Wood & Barmett，1964; 
Fumess & Costa，1975). Colocalization 0fAT2 with adrenaline cells by in situ 
hybridization with PNMT mRNA as a probe and with noradrenaline cells by 
glyoxylic acid-induced histofluorescence in adrenal can give hints as to the possible 
involvement 0fAT2 in the regulation ofcatecholamine synthesis. In bovine adrenal, 
k has already been indicated that angiotensin binding sites were present in higher 
density over adrenaline cells at the outer margins of the adrenal medulla (Marley et 
al., 1989;Wanetal., 1989). 
Not only is the physiological significance 0fAT2 receptor in adrenal glands 
unknown，its function in various tissues remains obscure. Elucidation ofthe role of 
AT2 binding sites is critical as part ofthe understanding ofthe actions ofAng E. The 
fUnction ofthe AT2 receptor remains of interest because ofits specific differential 
localization and enhanced expression in neonatal rats. There are several factors that 
hamper the characterization ofthe fimction ofthe AT2 sites. The available selective 
AT2 ligands have often been used at concentrations at which they were no longer 
subtype-selective (Brechler et al., 1993). CGP 42112A is a modified peptide and can 
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show partial agonist effects (Brechler et al., 1993). All ofthe AT2 ligands could 
inhibit agonist binding to ATi (Balla et al” 1991)，or could displace losartan, a ATj-
specifie antagonist, from protein-binding sites, giving rise to higher free level of 
losartan as has been shown in the renal hypertensive rat (Whitebread et al., 1991). 
One indirect approach to determine a distinct role of AT2 receptors is to study their 
tissue/cell distribution and their developmental regulation, tomunochemical 
methods are devoid of the above problems arisen because antagonists binding are 
not required in the demonstration of receptor subtypes. 
Despite the various efforts put in devising a protocol of suitable conditions 
for applying Thy-ATj antibodies in immunohistochemical staining, negative staining 
results were obtained for all the possible conditions undertaken when rat adrenal 
glands were used. This could be either because ATi was absent, or because it was 
present but has failed to bind to the antibodies. The first reason seemed impossible 
because various reports had already pointed out the abundant presence ofATi in rat 
adrenal cortex using autoradiography (Chiu et al., 1989a). On the other hand, there 
are various possible causes of negative staining. The conditions of staining might 
have been suboptimal for visualization in the tissue. However, efforts had been put 
in varying various conditions in tum. For example, different incubation temperature, 
types of fixative, durations of fixation, concentrations of first antibody, types and 
concentrations of second antibody as well as the use of ABC method were 
employed. Still, negative results were obtained. 
Another reason for negative staining might be that the AT! receptor was 
inaccessible because of penetration problems. Labeled antibodies are relatively large 
mokculcs compared with other staining reagents. Thus penetration difficulties and 
steric hindrance were potential problems. Ifpenetration problems should materialize, 
the accessibility of the tissue antigen ATi might be increased by immersing the 
tissues in organic solvents or detergents to break down lipids. However, positive 
result was still unattainable despite the various detergents (Triton-X 100, Tween 20) 
added to the incubating medium to enhance penetration. Dehydration ofthe sections 
89 
by graded ethanol solutions was also proved fruitless. It was concluded that the Thy-
ATi antiserum raised may not be suitable for immunohistochemical studies although 
it could be used for immunoblotting. However, a possibility could not be excluded is 
that the C-terminal tail of ATi receptor was so tightly associated with other proteins 
that it was unavailable for antibody interaction. 
Although cGMP formation (Bottari et al., 1992) and ion channel activity 
(Kang et al., 1992) have been suggested to be coupled to activation 0fAT2 receptor, 
the intracellular signaling pathways of AT2 receptors remains to be elucidated. 
Although the present study did not provide an answer to these questions, it suggested 
the possibility of studying the signaling pathways involved by immunochemical 
methods using the antibodies raised. The applicability ofimmunoprecipitation as a 
feasible method for studying cellular signaling pathways was illustrated by previous 
studies (Blackshear et al., 1988). As mentioned earlier, the antibodies were raised 
against a peptide putatively located at the intracellular C-terminal tail of the AT2 
receptor，antibody binding will not hinder the binding of ligands. Moreover, the 
putative intracellular loops of the seven-transmembrane receptor has been implied in 
the coupling with signaling molecules. Thus, immunoprecipitation using the Thy-
AT^ 2 antibodies should result in the isolation ofsignaling molecules associated with 
Al^ 2 receptor. Hence, immunoprecipitation can be performed in the future to address 
these problems with the Thy-AT2 antibodies available. After immunoprecipitation, 
the proteins isolated can be tested for size, type, sequence and activity! 
tomunoprecipitation can also provide definite proof of antibody-receptor 
interaction. The receptor complex can be reconstituted after being precipitated. The 
complex can then be tested for ability to bind ^^ -^Ang E and subsequent 
displacement with pharmacological antagonists. Identification of activated 
intracellular signaling messengers may provide potential cellular targets for 
development of specific functional AT2 receptor antagonist and/or agonist. 
The possibility that angiotensin receptors are multimeric has been suggested 
by various studies (Siemens et al., 1994; Yee et al.，1994). Ifphysical interactions do 
90 
exist between angiotensin receptors andvW other proteins, immunoprecipitation with 
antibodies against angiotensin receptor may result in simultaneous precipitation of 
all associated proteins, whose properties and identities can be studied. 
With the availability of AT2 antibodies applicable in immunohistochemistry, 
ultrastructural immunohistochemistry represents yet another promising direction for 
fUture studies. Further mapping by transmission electron microscopy will determine 
the subcellular location of angiotensin receptor immunoreactivity which is crucial to 
the understanding of its functions especially in neurons. For example, Ang H 
induced muscle contraction both on resting and electrically stimulated rat vas 
deferens (Trachte, 1984; Trachte et al., 1990; Sum & Cheung, 1995; Sum et al., 
1996). Potentiation of electrically-stimulated contraction seemed to suggest a pre-
synaptic locus for the action of angiotensin. Ultrastructural immunohistochemistry 
should allow us to distinguish the presynaptic locations from the postsynaptic sites 
ofangiotensin receptors. 
The lack ofpancreatic response to angiotensin was suggested by the inability 
ofangiotensin E to stimulate an increase in a-amylase release from rat pancreas. It 
was possible that angiotensin expresses its effect on rat pancreas in form of 
physiological functions other than a-amylase release, such as stimulation of 
bicarbonate secretion. Alternatively, the angiotensin receptor in rat pancreas might 
not be functional with a yet unidentified cause. However, a pancreatic acinar cell 
line, AR4-2J, does express sensitivity to angiotensin in terms ofenhanced a-amylase 
release (Cheung, W.T., unpublished data, manuscript in preparation). Thus, this 
provided justification for the use of assay of a-amylase release to study pancreatic 
sensitivity to angiotensin. Besides, the AR4-2J cell line also represents a promising 
model for the investigation of expression offunctional angiotensin receptors. It is of 
interest to note that AR4-2J is a tumor cell line (Jessop & Hay, 1980), and 
angiotensin has been suggested to promote cell growth (Geisterfer, 1988; Fluharty & 
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Reagan, 1989; Sadoshima et al., 1993 )• Therefore, AR4-2J cells can also be used to 
study the possible role of angiotensin in tumorigenesis. 
Further characterization of the RAS is particularly important, since it has 
been implicated in the pathogenesis of disorders such as hypertension (Hoffman et 
al., 1977) and atherosclerosis (Schelling et al., 1991). The design of potent and 
selective antagonists based on the biology ofthe receptor subtypes could lead to the 
development ofnovel drugs with increased specificity and reduced side effects. 
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Normal goat serum (DAKO) 
Peroxidase-conjugated goat anti-rabbit immunoglobulins (DAK。） 
Biotinylated goat anti-rabbit immunoglobulins (Vector) 
Enzyme 
a-amylase ( Sigma )，E.C. 3.2.1.1 
(PMSF-treated; from porcine pancreas; one unit liberates 1.8mg of maltose 
from starch in 3 min at pH6.9 at 20°C) 
Peptide 
Partial peptides of ATi and AT2 were obtained from Research Genetics. 
Angiotensin H (AngH) peptides and Cholecystokinin (CCK) peptides were obtained 
from Peninsula Laboratories. 
Their sequences are as below : 
ATi : H-Lys-Met-Ser-Thr-Leu-Ser-Tyr-Arg-Pro-Ser-Asp-Asn-Amide 
AT2 : H-Ghi-Gly-Lys-Arg-Glu-Thr-Met-Ser-Cys-Arg-Lys-Amide 
AngE : Asp-Arg-Val-Tyr-Ile-His-Pro-Phe 
CCK : Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 
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Protein Standard 
Protein standard marker for SDS-PAGE was from New England BioLabs: 
Prestained protein marker, broad range; includes MBP-P-galactosidase 
(175,000), MBP-paramyosin (83,000)，glutamic dehydrogenase (62,000), 
aldolase (47,500), triosephosphate isomerase (32,500), p-lactoglobulin A 
(25,000), lysozyme (16,500), andaprotinin (6,500). 
Chromatography Media 
Sephadex G-25 (Sigma) 
(Beads for gel filtration prepared by cross-linking dextran with 
epichlorohydrin; fractionation range for globulin proteins = mw 1000-
5000; 
dry bead diameter = 50-150 ^m; bed volume = 4-6 ml per gram) 
Affi-Gel 102 (BIO-RAD) 
(Aminoalky agarose gel; particle size 二 70-300^m; capacity = 15.4 
^mole/ml) 
Reagent 
The following reagents were from BDH Laboratory Supplies : 
Ethanolamine, CH2(OH).CH2NH2 
Formaldehyde Solution (25%), H.CHO 
2-Mercaptoethanol, HS.CH2CH2OH 
NNN'N'-Tetramethylethylene Diamine (TEMED) 
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The following reagents were from SIGMA Chemical Co.: 
Folin & Ciocalteu,s Phenol Reagent (2.0N) 
Freund's Adjuvant, Complete 
(Each ml contains: l.Omg Mycobacterium tuberculosis, heat killed & dried; 
0.85 ml paraffin oil; 0.15 ml mannide monooleate) 
Freund's Adjuvant, Licomplete 
Nonidet P-40, Nonionic detergent 
Triton-X 100 (t-Octylphenoxypolyethoxyethanol) 
Others : 
Dimethyl Sulfoxide (DMSO) 
from AMRESCO 
Glutaric Dialdehyde (25%) 
from Aldrich Chemical Company kic. 
Hydrogen Peroxide, H2O2 (30%) 
from E.Merck 
Vectastain Elite ABC Kits 
from Vector Laboratories 
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Chemical 
The following chemicals were from BDH Laboratory Supplies : 
Calcium Chloride 2-hydrate, CaCl2.2H2O 
Citric Acid，C(OH)(COOH)(CH2.COOH) 
Ethylenediamine Tetra-acetic Disodium Salt ^)DTA), 
[CH2.N(CH2.COOH).CH2.COONa]2.2H2O 
N-2-Hydroxyethylpiperazine-N-2-ethanesulphonic Acid (HEPES), C8Hi8N2O4S 
Magnesium Chloride 6-Hydrate, MgCl2.6H2O 
Methanol, CH3OH 
Orthoboric Acid, H3BO3 
Potassium Dihydrogen Orthophosphate, KH2PO4 
Sodium Carbonate Anhydrous, Na2CO3 
Sodium Dodecyl Sulphate, C12H25NaO4S 
Sodium Hydroxide, NaOH 
di-Sodium Tetraborate, Na2B4O7.1OH2O 
Trichloroacetic Acid, CCl3.COOH 
The following chemicals were from RDH Riedel-de Haen : 
Potassium Chloride, KC1 
Sodium Azide, NaN3 
Sodium Chloride, NaCl 
Sodium Hydrogen Carbonate, NaHCO3 
Sodium Dihydrogen Phosphate, NaH2PO4 
di-Sodium Hydrogen Phosphate, Na2HPO4 
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The following chemicals were from SIGMA Chemical Co.: 
Acetylcholine Chloride, C7Hi6NO2Cl 
Ammonium Sulfate, OSrH4)2SO4 
Amylose Azure, 
Potato amylose covalently linked with Remazol Brilliant Blue R 
Benzamidine Hydrochloride : Hydrate, C7H8N2.HCl 
di-Biotin (Vitamin H) 
Carbamylcholine Chloride (Carbachol), C6H15Cn^ 2O2 
Carbodiimide, CH2N2 
Cobalt Chloride Hexahydmte, CoCl2.6H2O 
Deoxycholic Acid (5p-cholan-24-oic acid-3a,12a-diol )，C24H39O4Na 
3,3'-Diaminobenzidine Tetrahydrochloride (DAB), Cl2H14N4.4HCl 
D-(+)-glucose, C6H12O6 
Glycerol, CsHgOs 
Glycine (Aminoacetic acid), C2H5NO2 
Imidazole (1,3-Diaza-2,4-cyclopentadiene), C3H4N2 
o-Phenylenediamine (1,2-Benzenediamine) Dihydrochloride (OPD), C6H8N2.2HCl 
Phenyl Methyl Sulfonyl Fluoride (PMSF), C7H7FO2S 
Potassium Phosphate Dibasic, Anhydrous, K2HPO4 
Semm Albumin, Bovine 
(Liitial fractionation by heat shock; Fraction V; 98-99%) 
Sodium Citrate Trisodium Salt: Dihydrate, C6H5Na3O7.2H2O 
Thyroglobulin, Bovine 
(Electrophoretically heterogeneous) 
Trizma Base (Tris[hydroxymethyl]amino-methane), C4HnNO3 
Trypsin L:Jiibitor, Type H-S: Soybean 
(One mg inhibits 1.6mg trypsin with an activity of 10,000 BAEE 
units/mg protein) 
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The following chemicals were from Boehringer Mannheim : 
Acrylamide, H2C=CHCONH2 







Spectrophotometer for protein assay was from Shimadzu: 
UV-VIS spectrophotometer, UV-1201 
Syringes for injection were from Terumo: 
Tuberculin with needle; sterile; single-use; lmL 
Columns for antibody purification were from BIO-RAD: 
Poly-Prep Chromatography Column 
Multiple well plates for ELISA were from Coming: 
Disposable sterile multiple well polystyrene plates; 
flat bottoms; 96 wells/plate 
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Vortex and shaker were from Thermolyne: 
Maxi Mixer 
Roto Mix 
Homogenizer for SDS-PAGE tissue preparation was from Biospec. Product, Jnc. : 
Dremel Tissue Tearer; Model 985-370 
Equipments for SDS-PAGE and westem blot were from Hoefer: 
SE 600 Dual Cooled Vertical Slab Unit 
TE52X Transphor Tank Electro-Transfer Unit 
Power supply for SDS-PAGE was from Pharmacia Biotech: 
Electrophoresis Power Supply ； EPS 600 
Fraction collectors for pancreas perfusion were from Pharmacia Biotech: 
LKBRediFrac 
Peristalic pumps for pancreas perfusion were from ATTA Chromatograph: 
Perista pump, AC-2110 
Glass microscope slides were from Raymond A Lamb- Laboratories Supplies: 
Blue Star glass microscope slides ； 
size 76x26mm; thickness 1.0/1.2mm 
Cryostat for sectioning was from Microm (Zeiss): 
Cryostat HM 505E 
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Miscellaneous 
Dialysis tubings were from Spectrum Medical Lidustries, Jnc.: 
Spectra/Por Molecular porous membrane tubing; mwco = 3500; 
flat width = 18mm; diameter = 11.5mm; vol/length = l.Oml/cm 
Nitrocellulose membranes for blotting were from Schleicher & Schnell: 
Protran Nitrocellulose, nucleic acid & protein transfer membrane; O.l^m 
Embedding medium for frozen tissue specimens was from Miles Inc.: 
Tissue-Tek O.C.T. Compound; 10.24% w/wpolyvinylalcohol; 
4.26% polyethylene glycol; 85.50% non-reactive ingredients 
Color reversal films were from Kodak: 
Ektachrome P1600 Professional EPH 135-36 
Ektachrome 400X Professional EPL 135-36 
Black & white negative films were from Ilford: 
FP4 Plus 125; 24x36mm 
Skimmed milk powder for immunoblotting buffer was from Anchor : 
Non fat instant milk powder; 
Each 100g powder contains : Protein 37.6g; Biotin 18^g; 
Calcium 1250mg; Phosphorus 1050mg; Magnesium 97mg; 









5% dry skimmed milk powder, 
0.05%NP-40, 
pH8.0. 
Citrate-phosphate buffer for ELISA 
24mM Citric acid, 
5imMNa2HPO4, 
pH5.0. 










Elution buffer for antiserum purification 
O.lM glycine buffer, 
pH2.5. 
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0.02mg/ml soyabean trypsin inhibitor, 
pH 7.4. 



















25^g/ml bromophenol Blue. 
Separating gel buffer. 4X for SDS-PAGE 
1.5M Tris-HCl, 
pH 8.8. 
Stacking gel buffer. 4X for SDS-PAGE 
0.5M Tris-HCl, 
pH 6.8. 
Substrate solution for immunoblotting 
0.70mM Diaminobenzidine (DAB), 
21 mM cobalt chloride, 
0.02% H2O2. 
Substrate solution for immunohistochemistrv 
100mM Tris-HCl, 








TPBS for immunohistochemistrv 
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